20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010558] Number: PF-[ADDRESS_1010559] Name: 20-valent pneumococcal conjugate vaccine 
(20vPnC)
[LOCATION_002] (US) Investigational New 
Drug (IND) Number:[ZIP_CODE]
European Clinical Trials Database 
(EudraCT) Number:2019-003308-11
Protocol Number: B7471014
Phase: 3
Short Title: Safety and Immunogenicity Study of 20vPnC in Healthy Children 
15 Months Through 17 Years of Age
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010560] 2021 •To be consistent with the European PIP modification 
approved in August 2021 added 2 secondary immunogenicity endpoints.
 
•Clarified that the primary immunogencity endpoints 
and the additional secondary endpoints are addressing consistencies with the approved European PIP modification.
Original protocol 13 Aug 2020 Not applicable (N/A)
This amendment incorporates all revision to date, including amendments made at the request 
of country health authorities and IRBs/ECs, and any protocol administrative clarification letter.C
CI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ..................... 8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................13
1.3. Schedule of Activities (SoA) ...................................................................................14
2. INTRODUCTION ...............................................................................................................16
2.1. Study  Rationale .......................................................................................................19
2.2. Background .............................................................................................................20
2.2.1. Clinical Overview .......................................................................................20
2.3. Ben efit/Risk Assessment .........................................................................................21
3. OBJECTI VES, ESTIM
ANDS, AND ENDPOINTS ...........................................................22
4. STUDY DESIGN .................................................................................................................24
4.1. Overall Design .........................................................................................................24
4.1.1. Approxi mate Duration of Participation for Each Participant .....................26
4.1.2. Approximate Number of Participants .........................................................26
4.2. Scientific Rationale for Study  Design .....................................................................26
4.3. Justification for Dose ..............................................................................................27
4.4. End of Study  Definition ..........................................................................................27
5. STUDY POPUL ATION
......................................................................................................27
5.1. I nclusion Criteria .....................................................................................................27
5.1.1. Cohort 1 and Cohort 2
................................................................................27
5.1.2. Cohort 3 and Cohort 4
................................................................................28
5.2.Exclusion Criteria ....................................................................................................29
5.2.1. Cohort 1 and Cohort 2
................................................................................29
5.2.2. Cohort 3 and Cohort 4
................................................................................30
5.3. L ifesty le Considerations ..........................................................................................32
5.3.1. Contraception (If Applicable) ................................ ................................ .....32
5.4. Screen Failures ........................................................................................................32
5.5. Temporary  Delay  Criteria .......................................................................................32
5.5.1. Criteria for Temporaril y Dela ying Vaccine Administration ...................... 32

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 45.5.2. Criteria for Temporaril y Dela ying Immunogenicity  Blood Draw ..............33
6. STUDY INTERVENTIO N
..................................................................................................33
6.1. Study  Intervention(s) A dministered ........................................................................33
6.1.1. Administration ............................................................................................33
6.1.2. Medical Devices .........................................................................................34
6.2. Prepa ration/Handling/Storage/Accountability ........................................................34
6.2.1. Preparation and Dispensing ........................................................................35
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................36
6.3.1. Allocation to Study Intervention ................................................................36
6.4. Study  Intervention Compliance ...............................................................................36
6.5. Concomitant Therapy ..............................................................................................36
6.5.1. Prohibited Concomitant Vaccines and Treatments
.....................................36
6.5.2. Permitted Concomitant Vaccines and Treatments ......................................36
6.5.3. Recording Prior and Concomitant Vaccine s and Treatments .....................37
6.6. Dose Modification ...................................................................................................37
6.7. I ntervention After the End of the Study ..................................................................37
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................38
7.1. Discontinuation of Study  Intervention ....................................................................38
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_1010561] to Follow -
up ....................................................................................................39
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................39
8.1. Efficacy  Assessments ..............................................................................................40
8.1.1. I mmunogenicit y Assessments ....................................................................40
8.1.2. Biological Samples .....................................................................................41
8.2. Safet y Assessments .................................................................................................42
8.2.1. Participant Electronic Diary ................................ ................................ .......42
8.2.2. Grading Scale for Prompted Events ...........................................................43
[IP_ADDRESS]. L ocal Reactions .........................................................................43
[IP_ADDRESS]. Sy stemic Events –Symptoms and Fever ..................................44
[IP_ADDRESS]. Use of 
Antipy retic/Pain Medication ..........................................47

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 58.2.3. Clinical Safety  Laboratory  Assessments ....................................................47
8.2.4. Pregnancy  Testing (If Applicable) ..............................................................47
8.3. Adverse Event s and Serious Adverse Events
..........................................................47
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......48
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................49
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................49
8.3.2. Method of Detecting AEs and SAEs ..........................................................49
8.3.3. Follow -up of AEs and SAEs .......................................................................49
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................50
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................50
[IP_ADDRESS]. Exposure During Pregnancy ......................................................50
[IP_ADDRESS]. Exposure During Breastfeeding ................................................52
[IP_ADDRESS]. Occupational Exposure .............................................................52
8.3.6. Cardiovascular and Death Events ...............................................................52
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_1010562] .............................................................53
[IP_ADDRESS]. Lack of Efficacy ........................................................................53
8.3.9. Medical Device Deficiencies ......................................................................53
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies .........53
[IP_ADDRESS]. Follow -
up of Medical Device Deficiencies...............................53
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to Sponsor ..............54
[IP_ADDRESS]. Regulatory  Reporting Requirements for Medical Device 
Deficiencies ................................ ................................ ....................... 54
8.3.10. Medication Errors .....................................................................................54
8.4. Tre atment of Overdose ............................................................................................55
8.5. Pharmacokinetics ....................................................................................................55
8.6. Pharmacod ynamics ..................................................................................................55
8.7. Genetics ...................................................................................................................56
8.8. Biomarkers ..............................................................................................................56
8.9. Health Economics ...................................................................................................56

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010563] 2021
PFIZER CONFIDENTIAL
Page 68.10. Study P rocedures...................................................................................................56
8.10.1. Visit 1 (Vaccination 1, Day 1)..................................................................568.10.2. Visit 2 (Follow-up: 28 to 42 Days After Visit 1, ie, Study Day 29 to 
43) ....................................................................................................................58
8.10.3. Visit 3 (6-Month Safety Collection [Telephone Contact] – 168 to 
196 Days After Visit 1)....................................................................................59
8.10.4. Unscheduled Visits ...................................................................................59
9. STATISTICAL C ONSIDERATIONS ................................................................................61
9.1. Estimands and Statistical Hypotheses .....................................................................61
9.1.1. Estimands....................................................................................................619.1.2. Statistical Hypotheses.................................................................................62
[IP_ADDRESS]. Cohort 1 and Cohort 2...............................................................[IP_ADDRESS]. Cohort 3 and Cohort 4...............................................................62
9.1.3. Multiplicity Considerations ........................................................................62
9.2. Sample Size Determination.....................................................................................639.3. Populations for Analysis .........................................................................................649.4. Statistical Analyses .................................................................................................65
9.4.1. Immunogenicity Analyses ..........................................................................659.4.2. Safety Analys es ..........................................................................................68
9.5. Interim Analyses .....................................................................................................69
9.5.1. Analysis Timing..........................................................................................69
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................70
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............70
10.1.1. Regulatory and Ethical Considerations ....................................................70
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................70
10.1.2. Financial Disclosure .................................................................................7110.1.3. Informed Consent Process ........................................................................7110.1.4. Data Protection .........................................................................................72
10.1.5. Dissemination of Clinical Study Data ......................................................72CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010564] 2021
PFIZER CONFIDENTIAL
Page 710.1.6. Data Qualit y Assurance ............................................................................74
10.1.7. Source Documents....................................................................................7510.1.8. Study and Site Closure..............................................................................75
10.1.9. Publication Policy.....................................................................................7610.1.10. Sponsor’s Qualified Medical Personnel .................................................76
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7710.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................78
10.3.1. Definition of AE .......................................................................................7810.3.2. Definition of an NDCMC .........................................................................7910.3.3. Definition of SAE.....................................................................................7910.3.4. Recording/Reporting and Follow-up of AEs and/or SAEs.......................8110.3.5. Reporting of SAEs....................................................................................84
 
10.5. Appendix 5: Genetics ............................................................................................89
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ........9010.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................9110.8. Appendix 8: Medical Device Adverse Events, Adverse Device Effects, 
Serious Adverse Events, and Device Deficiencies: Definition and Procedures for Recording, Evaluating, Follow-up, and Reporting ..............................................[ADDRESS_1010565] ...................................................................................................92
10.8.3. Definition of Device Deficiency...............................................................9310.8.4. Recording/Reporting and Follow-up of AEs and/or SAEs and 
Device Deficiencies .........................................................................................94
10.8.5. Reporting of SAEs....................................................................................96
10.8.6. Reporting of SADEs.................................................................................97CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 810.9. Appendix 9: Country -Specific Requirements .......................................................97
10.10. Appendix 10: Abbreviations ...............................................................................[ADDRESS_1010566] OF TABLES
Table 1. Grading Scales for Local Reactions in Study  Participants .......................44
Table 2. Grading Scales for Sy stemic Events -Participants Who Are 
≥15Months to <2 Years of Age (Cohort 1) .............................................45
Table 3. Grading Scales for Sy stemic Events -Participants Who Are 
≥2 to 
<18Years of Age (Cohorts 2 -4) ...............................................................[ADDRESS_1010567] 1 AE in Each of Cohorts 1 
Through 4 ..................................................................................................63
Table 6. Probability (%) to Demonstrate Superiorit y of Immune Response of 
1Month After 20vPnC to Before 20vPnC ...............................................64

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010568] 2021
PFIZER CONFIDENTIAL
Page 91. PROTOCOL SUMMARY
1.1. Synopsis[COMPANY_007] is developi[INVESTIGATOR_007] a new 20-valent pneumococcal conjugate vaccine (20vPnC) candidate to 
expand protection against pneumococcal disease beyond that covered by [CONTACT_407382]. 20vPnC has the same composition as 13-valent pneumococcal conjugate vaccine (13vPnC; Prevnar 13
®/Prevenar 13®), but contains an 
additional 7 pneumococcal conjugates targeting serotypes responsible for a substantial burden of remaining pneumococcal disease. 20vPnC uses the same platform and contains the same excipi[INVESTIGATOR_126496] 7-valent pneumococcal conjugate vaccine (7vPnC; Prevnar
®) and 
13vPnC. Phase 2 safety and immunogenicity data in infants support further development of 20vPnC in the pediatric population.
This Phase 3, multicenter, single-arm study will be conducted at investigator sites in the 
[LOCATION_002].  
The purpose of this study 
is to generate safety and immunogenicity data in children in the setting of a well-established national infant immunization program of pneumococcal conjugate vaccine (7vPnC and subsequently 13vPnC).  This will inform potential use of 20vPnC in children ≥[ADDRESS_1010569] the additional 7 serotypes may offer benefit.
Approximately 800 children from ≥15 months to <18 years of age at the time of consent, 
provided by a parent/legal guardian, and assent (when age-appropriate and per local requirements), will be enrolled into 4 cohorts based on age (Cohort 1: ≥15 to <24 months, 
Cohort 2: ≥2 to <5 years, Cohort 3: ≥5 to <10 years, and Cohort 4: ≥10 to <18 years), 
[ADDRESS_1010570] 3 prior doses of 13vPnC will be required in children <5 years of age (Cohorts 1 and 2).  Participants will receive a single dose of 20vPnC.
On Day 1 of the study (Visit 1), participants will be assessed for eligibility and information 
will be collected, including medical history and 13vPnC vaccination history.  Blood will be collected prior to vaccination for immunogenicity assessments.  Participants will receive a single dose of 20vPnC, which will be prepared and administered by a qualified site staff member or designee.  Permitted routine pediatric vaccines may be given at the same time as 
study vaccination according to local or national recommendations, if not feasible to separate 
from the 20vPnC.  Participants will be observed for 30 minutes after vaccination and any reactions occurring during that time will be recorded as adverse events (AEs).  The participant’s parent(s)/legal guardian(s) will be provided with an electronic diary (e-diary)(or e-diary application), thermometer, and measuring device and instructed to collect prompted local reactions (redness, swelling, and pain at the injection site) and age-applicable systemic events (fever, decreased appetite, drowsiness/increased sleep, and irritability in Cohort 1; and fever, fatigue, headache, muscle pain, and joint pain in Cohorts 2-4) for 7 days following vaccination (Days 1 to 7, where Day 1 is the day of vaccination). Use of antipyretic/pain medications will also be prompted for and collected daily in the e-diary for 7 days following vaccination.  The participant’s parent(s)/legal guardian(s) will be instructed CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 10to contact [CONTACT_739595] >14 caliper 
units, severe pain at the injection site, or fever >40.0°C (>104.0 °F),or has an emergency  
room visit or hospi[INVESTIGATOR_059].
Participants will return for Visit 2, approximately  1 month (28 to 42 day s)after Visit 1.  
Information will be collected from the participant’s parent(s)/legal guardian(s) on AEs, 
including nonseriou s AEs, serious AEs (SAEs), and newly  diagnosed chronic medical 
conditions (NDCMCs) ,and e -diary  follow -
up (as needed).  Concomitant medications used to 
treat SAEs or NDCMCs occurring after the previous visit will be recorded .  Information on 
vaccines given since the previous visit will also be recorded .  Blood will be collected for 
immunogenicit y assessments.
Participants will have Visit 3, approximately  6 months (168 to 196 day s) after Visit 1. The 
sites will contact [CONTACT_126727]’s parent(s)/legal guardian(s) via telephone to inquire about 
SAEs and NDCMCs andconcomitant medications used to treat SAEs or NDCMCs since the 
previous visit.
Objectives, Estimands, and Endpoints
Objectives Estimands Endpoints
Prim ary Safety: Prim ary Safety: Prim ary Safety:
To describe the safety profile 
of 20vPnC In participants from each cohort receiving 
20vPnC and having safety data reported 
after vaccination:
The percentage of participants 
reporting prompted local reactions 
within 7 days after vaccination
The percentage of participants 
reporting prompted systemic events 
within 7 days after vaccination
The percentage of participants 
reporting AEs up to 1 month after 
vaccination
The percentage of participants 
reporting SAEs up to 6 months a fter 
vaccination
The percentage of participants 
reporting NDCMCs up to 6 months 
after vaccinationProm pted local reactions 
(redness, swelling ,and 
pain at the injection site)
Prom pted systemic events:
Cohort 1:  Fever, 
decreased appetite, 
drowsiness/ increased 
sleep ,and irritability
Cohort s 2through 4:  
Fever, fatigue,
headache, muscle 
pain, and joint pain
AEs
SAEs
NDCMCs

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 11Objectives Estimands Endpoints
Prim ary Immunogenicity: Prim ary Immunogenicity: Prim ary Immunogenicity:
Cohort 1 and Cohort 2: To
demonstrate that the serotype -
specific IgG concentrations
forthe 7 additional serotypes
1 month after 20vPn C are
superior to the corresponding 
IgG concentrations before 
20vPnCIn participants in com pliance with the key 
protocol criteria (evaluable participants):
Geom etric mean fold rises
(GMFRs) of serotype- specific IgG 
concentrations forthe 7 additional 
serotypes from before to 1 month 
after vaccinationPneumococcal 
serotype -specific IgG 
concentrations
Cohort 3 and Cohort 4: To 
demonstrate that the serotype -
specific opsonophagocytic 
activity ( OPA ) titers forthe 
7additional serotypes 1 month 
after 20vPnC are superior to 
the corresponding OPA titers 
before 20vPnCIn participants in com pliance with the key 
protocol criteria (evaluable participants):
GMFRs of serotype -specific OPA 
titers forthe 7 additional serotypes
from before to 1 month after 
vaccinationPneumococcal 
serotype -specific OPA
titers
Secondary Immunogenicity: Secondary Immunogenicity: Secondary Immunogenicity:
To further describe the 
immune responses to 20vPnC 
in Cohorts 1, 2, 3 ,and 4In evaluable participants:
Percentage of participants with 
predefined serotype -specific IgG 
concentrations for the 7 additional 
serotypes at 1 month after vaccination 
in Cohort 1 only
Percentage of participants with 
≥4-fold rise in serotype -specific OPA 
titers for the 7 additional serotypes 
from before t o 1 month after 
vaccination in Cohorts 2, 3 ,and 4
only
Serotype -specific IgG geometric 
mean concentrations ( GMCs )forthe 
20vPnC ser otypesbefore and 
1month after vaccination
GMFRs ofserotype -specific IgG 
concentrations forthe 13vPnC 
serotypes from before to 1 month 
after vaccination (in Cohorts 1 and 2 )
GMFRs ofserotype -specific IgG 
concentrations forthe 20vPnC 
serotypes from before to 1 month 
after vaccination (in Cohorts 3 and 4)Pneumococcal 
serotype -specific IgG 
concentrations
Pneumococcal 
serotype -specific OPA 
titers

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 12Objectives Estimands Endpoints
Serotype -specific OPA geometric 
mean titers (GMTs )forthe 20vPnC 
serotypes before and 1 month after 
vaccination
GMFRs ofserotype -specific OPA 
titers forthe 20vPnC serotypes from 
before to 1month after vaccination
(in Cohorts 1 and 2 )
GMFRs ofserotype -specific OPA 
titers forthe 13vPnC serotypes from 
before to 1month after vaccination
(in Cohorts 3 and 4 )
Number of Participants
Approximately  800 participants (200/ cohort ) will be enrolled to achieve a target of 
720(180/ cohort ) evaluable participants at the follow -up time point [ADDRESS_1010571] 
cohorts ,documented history  of13vPnC vaccination:
Cohort 1: Approximately  200 children ≥15 months to <24 months ( <2 years) of age who 
have been previousl y vaccinated with at least 3 doses of 13vPnC .
Cohort 2: Approximately  200 childre n≥2 years to <[ADDRESS_1010572] 3 doses of 13 vPnC .
Cohort 3: Approximately  200 children ≥5 years to <10 y ears of age regardless of 
documentation of previous vaccination with 7vPnC or 13 vPnC .
Cohort 4: Approximately  200 children ≥10 y ears to <18 y ears of age regardless of
documentation of previous vaccination with 7vPnC or 13 vPnC .
Duration of Participation for Each Participant
Each par ticipant will participate in the study  for approximately  6 months
.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010573] 2021
PFIZER CONFIDENTIAL
Page 13 
 
 
Statistical Methods
The primary safety objective will be evaluated by [CONTACT_407384], systemic events, and AEs, including SAEs and NDCMCs, for each age cohort.
The primary immunogenicity objectives will be evaluated by [CONTACT_739596] 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) 1 month after 20vPnC to before 20vPnC in Cohorts 1 and 2, and superiority of OPA titers for the 7 additional serotypes 1 month after 20vPnC to before 20vPnC in Cohorts 3 and 4. Superiority for a serotype in each cohort will be declared if the lower bound of the 2-sided 95% confidence interval (CI) for the IgG (or OPA) GMFR from before 20vPnC to 1 month after 20vPnC for that serotype is greater than 1.
1.2. Schema
Not applicable.CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 141.3.Schedule of Activities (SoA)
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol.
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluat ions or 
assessments required to protect the well -being of the participant.
Visit Number 1 2 3
Visit ID Vaccination Follow -up Visit Follow -up Phone Calla
Study Interval Visit Day 1 1-Month Visit 6-Month Phone Call
Visit Window (Days) 28-42 Days
After Visit 1168-196 Days After Visit 1
Obtain informed consent/assent X
Assign participant number via IRT X
Record demography X
Perform clinical assessment, including medical history X
Obtain prevaccination temperature (measured as appropriate for age) X
Record nonstudy vaccinationsbX X
Record concomitant medicationscX X X
Urine pregnancy test (if applicable) X
Contraception check (if applicable)dX X
Revie w inclusion and exclusion criteria X
Revie w temporary  delay criteria X X
Revie w continued eligibility X
Obtain blood sampleeXfX
Assign an investigational product container number via the IRT X
Administer investigational product into left leg (option for Cohort 1 only) or left arm Xg
Administer and record routine pediatric vaccinations, as applicablehX
Observe and record reactions for [ADDRESS_1010574] administration X

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 15Visit Number 1 2 3
Visit ID Vaccination Follow -up Visit Follow -up Phone Calla
Study Interval Visit Day 1 1-Month Visit 6-Month Phone Call
Visit Window (Days) 28-42 Days
After Visit 1168-196 Days After Visit 1
Provide parent(s)/legal guardian(s) with an e -diary (device or application, as appropriate) , 
thermometer ,and measuring device and instruct to collect prompted local reactions and 
systemic events anduse of antipyretic/pain medicationsiX
Provide a participant contact [CONTACT_1137] X X
Revie w and/or collect e -diary (if applicable)jX
Record and report adverse events X------------- --------- X
Record and report SAEs and NDCMCskX--------------------- ----------------- ----------------- X
Abbreviations: IRT = interactive response technology; NDCMC = newly diagnosed chronic medical condition.
a.This telephone contact [CONTACT_161705] 6 months after study vaccination; this contact [CONTACT_739597], unless the parents/legal guardians have withdrawn consent .
b.For Cohort s [ADDRESS_1010575] and document the conversation and the participant’s affirmation in the source notes.
e.For Cohorts 1 and 2:  ~5 mL; for Cohort s 3 and 4:  ⁓10 mL .
f.Blood sample will be collected prior to vaccination.
g.Remind the participant’s parent(s)/legal guardian(s) that the use of prophylactic antipyretic/pain medication, while permitted, is not r ecommended on the 
dayof investigational product administration (before or after vaccination).
h.Administer perm itted routine pediatric vaccinations (as applicable) after the investigational product into a limb other than the site of the 20vPnC injection.
Prohibited and p ermitted vaccines are described in Sections 6.5.1 and 6.5.2 , respectively.
i.The participant’s parent(s)/legal guardian(s) will record prompted local reactions and systemic events and antipyretic/pain m edication in an e -diary for the 
7days following vaccination. The participant’s parent(s)/legal guardian(s) will be instructed to contact [CONTACT_739598] >14 caliper units, severe pain at the injection site (left leg [option for Cohort 1 only] or left arm), a fever >40.0°C (>104.0°F), or an 
emergency room visit or hospi[INVESTIGATOR_059].
j.Designated site staff will review e -diary data online at frequent intervals (daily is optimal) for the 7 days follo wing vaccination to evaluate participant 
compliance and as part of the ongoing safety revie w.
k.AnNDCMC is defined as a disease or medical condition, not previously identified, that is expe cted to be persistent or otherwise long -lasting in its effects.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 162.INTRODUCTION
Pneumococcal Disease
Streptococcus pneumoniae are gram -positive encapsulated cocci that are a leading cause of 
bacteremia, bacterial meningitis, pneumonia, and acute otitis media (AOM) and continue to 
be a major global public health concern.1,2,3Serious pneumococcal disease may  occur at any  
age; however, children <5 y ears and adults ≥ 65 years of age are at particularly  increased 
risk.4  Individuals with certain comorbidities and immunocompromising conditions are also 
at risk, especiall y persons with chronic heart, lung, liver, and renal disease, as well as those 
who are functionall y asplenic.  The global burden of pneumococcal disease has been 
substantially  impacted b y pneumococcal conjugate vaccines.  S pneumoniae caused an 
estimated 14.5 million cases of serious disease and 826,000 deaths annuall y in children 
<5years of age prior to introduction of pneumococcal conjugate vaccines.2  It has been 
estimated that in 2015, several years followin g introduction of pneumococcal conjugate 
vaccines into the national infant immunization programs of more than 100 countries, the 
global disease burden had declined, but S pneumoniae still accounted for 2.6 million cases of 
severe pneumococcal disease, 332, 000 deaths in children <5 y ears of age, and 11% of deaths 
in children between the ages of 1 and 5 years.5
The overall invasive pneumococcal disease (I PD) burden was estimated in [ADDRESS_1010576] 
decreased approximately  90% in the population <5 y ears of age in the [LOCATION_002] since the 
introduction of pneumococcal conjugate vaccines; however, there was a slight increase in the 
proportions of I PD cases associated with hospi[INVESTIGATOR_059] (63% to 71%), and the I PD case 
fatality rate was also slightly  but statistical ly significantly  increased (2% to 3%) in that age 
group.6This is due to the decrease in disease due to the serot ypes in 7vPnC and 13vPnC.  
However, disease due to seroty pes not covered by  [CONTACT_407386], and causes 
significant morbidit y and mortality .
National I PD surveillance data in England and Wales for the epi[INVESTIGATOR_904] y ear 
2016- 2017, approximately  10 y ears after the introduction of 7vPnC in the national infant 
immunization program and 6 y ears after the introduction of 13vPnC, showed 
that the overall 
incidence of IPD was 9.87 per 100,000 population, with an incidence of 13.90 per 
100,000 population <2 years of age .7The data for England and Wales are consistent with the 
patterns observed in data from the European Union (EU) for 2017, which showed an overall 
IPD incidence of 6.2 cases per 100,000 population, with an incidence of 14.5 per 
100,000 infants under 1 y ear of age .8  Pediatric surveillance studies conducted between 
2007 and 2013 in 8 US children’s hospi[INVESTIGATOR_600], and between 1997 a
nd 2010 in a referral center 
in Utah, found case fatality  rates of 10% and 13% with pneumococcal meningitis, 
respectivel y.  These studies also found that between 52% and 63% of children surviving 
pneumococcal meningitis experience neurologic sequelae.9,10More recent pediatric 
surveillance conducted between 2014 and 2017 in 8 US children’s hospi[INVESTIGATOR_634662] 
13vPnC introduction in 2010 showed that 76.1% of residual IPD was caused by  [CONTACT_105]- 13vPnC 
seroty pe isolates.11Serotypes 10A, 12F, 15B/15C, 22F ,
and 33F accounted for 36% of 
isolates causing IPD.  The most common clinical presentations of IPD due to non -13vPnC 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 17seroty pes included bacteremia (49.6%), meningitis (19.1%), and pneumonia (18.8%). These 
data demonstrate the continued need for expanded seroty pe coverage.
Surveillance studies conducted in 2010 -2012 by  [CONTACT_100571] (CDC) found that S pneumoniae remains among the most common pathogens 
identified in community -acquired pneumonia (CAP) requiring hospi[INVESTIGATOR_739586].12,13It was the most common bacterial cause in 
children <2 years of age, even in the setting of a 43% reduction in CAP hospi[INVESTIGATOR_739587] 1997-1999 and2007 -2009, due to the introduction to 
7vPnC.12,14Surveillance reported in 2017 b y the European Centre for Disease Prevention 
and Control (ECDC) showed that among cases of IPD for which the clinical presentation was 
known across all age groups, bacteremic pneumonia was reported in 42% of cases. The most 
common clinical presentation
sin children <5 years of age w eresepticemia and bacteremic 
pneumonia ( 1-4 year olds )and meningitis (<1 year old) .8These data suggest that 
Spneumoniae remains an important cause of serious disease in the [LOCATION_002] and 
worldwide.
AOM is a common childhood illness, with the 2011 visit rates of 0.82 and 0.81 visits per
AOM/child- year in children <2 years of age and 2 to 6 y ears of age, respectively , and 
represents a significant medical burden.15  S pneumoniae is one of the common bacter ial 
causes of AOM, and accounted for an estimated 850,000 outpatient and 125,000 emergency  
room visits in the [LOCATION_002] in 2004 in children <5 years of age, representing a significant 
burden on the healthcare sy stem.3While AOM is generall y not considered a serious disease, 
it does carry  the risk of more serious complications.  These complications can range from the 
development of chronic or rec urrent otitis media necessitating surgical intervention 
(tympanostom y tube placement), and accompanied by  [CONTACT_407388] s, to invasive extension leading to mastoiditis and 
meningitis.
Although the introduction of pneumococcal conjugate vaccines into the [LOCATION_002] and 
other national infant immunization programs has brought about substantial reductions in the 
various manifestations of pneumococcal disease in pediatric (infants and chi ldren) 
populations, a substantial burden of pneumococcal disease remains. Serotypes not included 
in existing vaccines continue to contribute significantly  to morbidity  and mortality .
Vaccines to Prevent Pneumococcal Disease
Pneumococcal Polysaccharide Vac cines
The poly saccharide capsule has been identified as an important virulence factor for this 
pathogen.  While more than [ADDRESS_1010577] the specific 
seroty pe bind to the capsule and promote complement- mediated opsonophagocy tic killing 
and clearance of the organism.18  Pneumococcal disease can be preve nted with 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 18polysaccharide -based vaccines that induce antibody  responses with functional 
(opsonophagocy tic) activity  and target the capsular serot ypes responsible for disease.[ADDRESS_1010578] been licensed since the 1970s.  One such 
vaccine, the 23 -valent pneumococcal poly saccharide vaccine (PPSV23), has been licensed in 
the [LOCATION_002] since 1983.20,21PPSV23 contains capsular pol ysaccharides for 
23seroty pes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 
20, 22F, 23F, and 33F).  Pneumococcal vaccines containing free pol ysaccharides such as 
PPSV23 elicit a T -cell–independent immune response.  Unconjugated pol ysaccharide 
vaccines do not induce robust responses in certain populations (eg, immunocom promised 
persons, 
and children < 2yearsof age ), nor do they generate immunologic memory , so that 
their protective effect wanes over 2 to 5 years.4,21,22,23  Moreover, their ability  to prevent 
nonbacteremic pneumonia, CAP, and AOM is limited or lacking.19
,23,24,25,26  In addition, 
polysaccharide vaccines do not reduce vaccine -type (VT) nasophary ngeal carriage, which is 
important for herd immunity .26  PPSV23 is not recommended for children <2 y ears of age 
and only  recommended in children >2 years of age who are at high risk for I PD to provide 
some degree of protection from disease caused b y serotypes not covered b y existing 
pneumococcal conjugate vaccines.19
Pneumococcal Polysaccharide Conjugate Vaccines
Pneumococcal conjugate vaccines contain poly saccharides that are covalently  linked 
(conjugated) to an immunogenic protein.  This modification results in T -cell–dependent 
immune responses, which have been shown to be protective in y oung children, older adul ts, 
and populations with high -risk conditions.22,277vPnC was the first pneumococcal conjugate 
vaccine to be licensed (2000) and was indicated for prevention of pneumococcal disease in 
infants and young children on the basis of efficacy studies.  7vPnC contained capsular 
polysaccharide conjugates for 7 pneumococcal seroty pes (4, 6B, 9V, 14, 18C, 19F, and 23F), 
each covalentl y linked to cross -
reactiv e material 197 (CRM 197), a nontoxic variant of 
diphtheria toxin.  These 7 seroty pes were responsible for approximately  80% to 90% of IPD 
in children <5 years of age in the [LOCATION_002] and approximately  60% to 80% of IPD in the 
same age group in Europe at that time (1998- 2000).28,29,30,31,[ADDRESS_1010579] 
clinically /radiographically  defined pneumonia.[ADDRESS_1010580] effects, 
with a 92% reduction of 7vPnC VT I PD in older adults ≥65 years of age.40
13vPnC was developed to expand seroty pe coverage and was licensed in the [LOCATION_002] in
2010.  13vPnC includes the same Spneumoniae seroty pes as 
7vPnC and an additional 
6polysaccharide conjugates for serot ypes 1, 3, 5, 6A, 7F, and 19A.27,31,41  The vaccine was 
licensed for use in infants and y oung children based on comparisons of seroty pe
-specific 
serum IgG antibody  concentrat ions to 7vPnC, with supportive data to demonstrate the 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010581] CAP due to serotypes contained in 13vPnC in adults 65 years of age and older.
42  13vPnC has replaced 7vPnC and is licensed in the [LOCATION_002] 
and many other countries, with national recommendations for use in children and older adults.
43,44,45,46  It has also been prequalified by [CONTACT_38375] (WHO) for 
use in national infant immunization programs in lower- and middle-income countries.47,[ADDRESS_1010582] 13vPnC VT IPD in the vaccinated population.
49,50,51
Development of 20vPnC
The 20vPnC candidate is modeled after 7vPnC and 13vPnC, and contains polysaccharides of 
capsular serotypes of S pneumoniae , each covalently linked to CRM 197. The amount of 
polysaccharide (2.2 μg/dose) selected for each new serotype (8, 10A, 11A, 12F, 15B, 22F, 
and 33F) contained in the 20vPnC candidate mirrors the approach taken for the addition of the 6 new serotypes when developi[INVESTIGATOR_007] 13vPnC.  The 20vPnC candidate contains the same components as 13vPnC, including the 13 polysaccharide conjugates, excipi[INVESTIGATOR_840] (polysorbate 80, succinate buffer, sodium chloride), and aluminum phosphate, in addition to the 7 new polysaccharide conjugates.  Additional epi[INVESTIGATOR_407369] 7 serotypes and the preclinical program are described in the 20vPnC investigator’s brochure (IB). The vaccine is being developed for use in pediatric and adult populations.
2.1. Study Rationale
 The purpose of this study is to provide safety and immunogenicity 
data with 20vPnC in children ≥15 months to <18 years old in the setting of well-established 
national infant immunization program with a pneumococcal conjugate vaccine (7vPnC and 13vPnC in the [LOCATION_002]).  This will inform potential use of 20vPnC in children ≥[ADDRESS_1010583] the 6 serotypes unique to 13vPnC.
52
Descriptive 
immunogenicity data for all 20 vaccine serotypes will also be generated.CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 202.2.Background
20vPnC is being developed to further expand protection against the global burden of 
vaccine -preventable pneumococcal disease in children and adults over that of 13vPnC.  
20vPnC contains the seroty pes present in 13vPnC plus 7 new sero types (8, 10A, 11A, 12F, 
15B, 22F, and 33F) individually  conjugated to CRM 197.  As noted above, 20vPnC uses the 
same platform and contains the same excipi[INVESTIGATOR_126496] 7vPnC and 13vPnC.  These 7 additional 
seroty pes were selected based on their relative prevalen ce as a cause of IPD, their 
generalized geographic distribution, and other factors that would support inclusion, such as 
the presence of antibiotic resistance (11A, 15B), association with outbreaks (8, 12F), and 
greater disease severit y (eg, meningitis, mo rtality ) (10A, 11A, 22F).53,54,55,56,57,58,59,60,61,62,63,[ADDRESS_1010584] a long -standing association with serious pneumococcal disease and 
are responsible for a substantial burden of remaining pneumococcal disease.
The incidence of IPD due to these 7 serot ypes in children <[ADDRESS_1010585] several years, and these seroty pes cause a 
significant amount of I PD in children.65,66,67,68,69,70,71  These 7 serotypes contribute to the 
burden of IPD in the [LOCATION_002] and elsewhere. It is estimated that between 2015 and 
2016, these 7 serot ypes accounted for 
35% of IPD in children 5 through 17 y ears of age and 
39% of IPD in children <5 years of age in the U nited States.72In the EU, according to the 
ECDC annual I PD epi[INVESTIGATOR_93282]2017, approxi mately 75% of cases of IPD in 
children <5 years of age were caused b y a serot ype not in 13vPnC, increased from 63% in 
2013. Five of the [ADDRESS_1010586] frequent serotypes causing 
disease in 5- to 14 -year-olds in the ECDC report .8
A meta -analy sis of seroty pes causing IPD in children <[ADDRESS_1010587] introduced higher -valent pneumococcal conjugate vaccines (such as 13vPnC) 
showed that, overall, these 7 serot ypes accounted for approximately  70% of disease not due 
to the 13vPnC ty pes.67
2.2.1. Clinical Overview
Safety  and immunogenicity  data f rom a 20vPnC Phase 1 study  (B7471001) conducted in 
healthy adults 18 through 49 years of age demonstrated that the vaccine induces immune 
responses (IgG and OPA responses) to the [ADDRESS_1010588] a 
safet y profile similar to 13 vPnC .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010589] 2021
PFIZER CONFIDENTIAL
Page 21A Phase 2 study (B7471003) of 20vPnC in a pediatric population, healthy infants 
≥42 to≤98 days of age, has been conducted. The study randomized 460 US participants to 
receive either blinded 20vPnC or 13vPnC. Safety and immunogenicity data are available from the study.  20vPnC was well tolerated in the infants and the safety profile was similar tothat of the 13vPnC group in the study and was consistent with other pneumococcal conjugate vaccines. Immune responses of IgG after 3 doses of 20vPnC were similar to those in the 13vPnC group. These data support continued development of 20vPnC in a pediatric population.
2.3. Benefit/Risk Assessment
The 20vPnC investigational product contains the same components and excipi[INVESTIGATOR_739588] 13vPnC, but also contains the polysaccharide conjugates for the [ADDRESS_1010590] common AEs noted in the pediatric population 15 months through 17 years of age after vaccination with 13vPnC are primarily related to local reactions (injection site pain or tenderness, redness, and swelling) and systemic events (fever, irritability, decreased appetite, and increased sleep).  This includes data from children with prior 7vPnC immunization.
73,74
In a randomized, active-controlled, double-blind study with a 2-arm parallel design
(B7471003), 20vPnC was administered to 460 infants ≥42 to ≤[ADDRESS_1010591] common AEs after 20vPnC administration were local reactions (pain, redness, and swelling at the injection site) and systemic events (irritability, drowsiness/increased sleep, and decreased appetite).
As with any vaccine, an allergic reaction can occur. The allergic reaction can vary from skin 
rash to swelling of the face or lips, wheezing, and/or shortness of breath. A severe allergic reaction (anaphylactic shock, collapse, or shock-like state [hypotonic-hyporesponsive epi[INVESTIGATOR_1865]]) may also occur. There may also be additional risks related to the vaccines administered in the study that are not known at this time.
Risks that may be associated with study procedures include risks from blood draws, 
including pain, swelling, bruising, and infection where blood is taken.
Safety assessments described in the protocol and ongoing review of safety data by [CONTACT_407390].  
 
In the B7471003 study, 20vPnC induced immune responses 
to the pneumococcal serotypes in the vaccine. This suggests that protection against pneumococcal disease will be similar to that of 13vPnC. If 20vPnC is successful in Phase 3 studies, and approved, it is anticipated to provide a public health benefit by [CONTACT_739599].
CC
I
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 22[COMPANY_007] considers that the available information from Study  B7471003 with 20vPnC, the 
available safet y profile of similar pneumococcal conjugate vaccines (ie, 7vPnC and 13 vPnC ), 
and the limited risks from study  procedures support a favorable benefit -risk profile for 
20vPnC 
and this study .
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of 20vPnC may be found in the 20vP nC IB,which is the single reference 
safet y document (SRSD) for this study.
3.OBJECTIVES, ESTIMAND S, AND ENDPOINTS
Objectives Estimands Endpoints
Prim ary Safety Prim ary Safety Prim ary Safety
To describe the safety profile of 
20vPnC In participants from each cohort
receiving 20vPnC and having safety 
data reported after vaccination:
The percentage of participants 
reporting prompted local 
reactions within 7 days after 
vaccination
The percentage of participants 
reporting prompted system ic 
events within 7 days after 
vaccination
The percentage of participants 
reporting AEs up to 1 month 
after vaccination
The percentage of participants 
reporting SAEs up to 6 months 
after vaccination
The percentage of participants 
reporting NDCMCs up to 
6months after vaccinationProm pted local reactions 
(redness, swelling ,and pain 
at the injection site)
Prom pted systemic events:
Cohort 1: Fever, 
decreased appetite, 
drowsiness/increased 
sleep ,and irritability
Cohort s 2through 4:  
Fever, fatigue, 
headache, muscle pain, 
and joint pain
AEs
SAEs
NDCMCs
Prim ary Immunogenicity Prim ary Immunogenicity Prim ary Immunogenicity
Cohort 1 and Cohort 2: To 
demonstrate that the 
serotype -specific IgG 
concentrations forthe 7 additional
serotypes 1 month after 20vPnC 
are superior to the corresponding 
IgG concentrations before 
20vPnCIn participants in compliance with 
the key protocol criteria (evaluable 
participants):
GMFR sof serotype -specific IgG 
concentrations forthe
7 additional serotypes from 
before to 1 month after 
vaccinationPneumococcal 
serotype -specific IgG 
concentrations

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 23Objectives Estimands Endpoints
Cohort 3 and Cohort 4: To 
demonstrate that the 
serotype -specific OPA titers for
the 7 additional serotypes 1 month 
after 20vPnC are superior to the 
corresponding OPA titers before 
20vPnCIn participants in com pliance with 
the key protocol criteria (evaluable 
participants):
GMFRs of serotype -specific 
OPA titers forthe 7 additional 
serotypes from before to 
1 month after vaccinationPneumococcal 
serotype -specific OPA titers
Secondary Immunogenicity Secondary Immunogenicity Secondary Immunogenicity
To further describe the immune
responses to 20vPnC in Cohorts 1, 
2, 3,and 4In evaluable participants:
Percentage of participants with 
predefined serotype -specific IgG 
concentrations for the 7 
additional serotypes at 1 month 
after vaccination in Cohort 1
only
Percentage of participants with 
≥4-fold rise in serotype -specific 
OPA titers for the 7 additional 
serotypes from before t o 1 
month after vaccination in 
Cohorts 2, 3 ,and 4 only
Serotype -specific IgG GMCs for
the 20vPnC serotypes before 
and 1 month after vaccination
GMFRs ofserotype -specific IgG 
concentrations forthe 13vPnC 
serotypes from before to 
1month after vaccination
(inCohorts 1and 2)
GMFRs ofserotype -specific IgG 
concentrations forthe 20vPnC 
serotypes from before to 
1month after vaccination
(in Cohorts 3 and 4)
Serotype -specific OPA GMTs 
forthe 20vPnC serotypes before 
and 1 month after vaccination
GMFRs ofserotype-specific 
OPA titers forthe 20vPnC 
serotypes from before to 
1month after vaccination
(inCohorts 1 and 2)
GMFRs ofserotype -specific 
OPA titers forthe 13vPnC 
serotypes from before to 
1month after vaccination
(inCohorts 3and 4)Pneumococcal 
serotype -specific IgG 
concentrations
Pneumococcal 
serotype -specific OPA titers

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010592] 2021
PFIZER CONFIDENTIAL
Page 24Objectives Estimands Endpoints
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
4. STUDY DESIGN
4.1. Overall DesignThis Phase 3, multicenter, single-arm study will be conducted at investigator sites in the 
[LOCATION_002]. 
 The purpose of this study is 
to provide safety and immunogenicity data in children in the setting of a well-established national infant immunization program of pneumococcal conjugate vaccine (7vPnC and CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 25subsequently  13vPnC ).  These data will inform potential use of 20vPnC in children 
≥15months of a ge where direct protection against the additional 7 serot ypes may offer 
benefit.
Approximately  800 children from ≥15 months to <18 y ears of age at the time of consent, 
provided by a parent/legal guardian, and assent (when age-appropriate and per local 
requirements ), will be enrolled into 4 cohorts based on age (Cohort 1: ≥15 to <24 months, 
Cohort 2: ≥2 to <5 y ears, Cohort 3: ≥5 to <10 y ears, and Cohort 4: ≥10 to <18 y ears), 
[ADDRESS_1010593] 3 prior doses of 13vPnC will be 
required in children <5 years of age (Cohorts 1 and 2).  Participants will receive a single dose 
of 20vPnC.
On Day  1 of the stud y (Visit 1), participants will be assessed for eligibility  and information 
will be collected includin g medical history  and 13vPnC vaccination history 
(see Section 6.5.3 ).  Blood will be collected prior to vaccination for immunogenicity  
assessments.  Participants will receive a single dose of 20vPnC, which will be prepared and 
administered b y aqualified site staff member or qualified designee.  
Permitted r outine 
pediatric vaccines (see Section 6.5.2) may be given at the same time as study  vaccination 
according to local or national recommendations, if not feasible to separate from the 20vPnC .  
Participant s will be observed for 30 minutes after vaccination and any reactions 
occurring 
during that time will be recorded as AEs .  The participant’s parent(s)/legal guardian(s) will 
be provided with an e -diary  (or e -diary  application), thermometer, and measuring device and 
instructed to collect prompted local reactions (redness, swelling , and pain at the injection 
site) and age -applicable systemic events (fever ,decreased appetite, drowsiness/increased 
sleep ,and irritability in Cohort 1; andfever, fatigue, headache, muscle pain, and joint pain in 
Cohort s 2
-4) for7 day s following vaccination. Use of antipy retic/pain medications will also 
be prompted for and collected dail y in the e -diary  for 7 day s after vaccination.  The 
participant’s parent(s)/legal guard ian(s) will be instructed to contact [CONTACT_739600] >14 caliper units, severe pain at the 
injection site, orfever >40.0°C (>104.0°F) ,or has an emergency  room visit or 
hospi[INVESTIGATOR_059].
Participant s will return for Visit 2, approximately  1 month (28 to 42 day s)after Visit 1
(study Day 29 to 43).  Information will be collected from the participant’s parent(s)/legal 
guardian(s) on AEs, including nonserious AEs, SAEs, and NDCMCs ,and e -diary  follow -up
(as needed).  Concomitant medications used to treat SAEs or NDCMCs occurring after the 
previous visit will be recorded . Information on vaccines given since the previous visit will 
also be recorded .  Blood will be collected for immunogenicity assessments.
Participants will have Visit 3, approximately  6 months (168 to 196 day s) after Visit 1. The 
sites will contact [CONTACT_2299]’s parent(s)/legal guardian(s) via telephone to inquire about 
SAEs and NDCMCs andconcomitant medications used to treat SAEs or NDCMCs since the 
previous visit.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010594] 2021
PFIZER CONFIDENTIAL
Page 26In the case of extreme circumstances, such as natural disasters or a pandemic, visits for 
follow-up or procedures may need to be conducted through other means (eg, telephone calls).
4.1.1. Approximate Duration of Participation for Each Participant
Each participant will participate in the study for approximately 6 months.
4.1.2. Approximate Number of Participants
Approximately 800 participants (200/cohort) will be enrolled to achieve a target of 
720 (180/cohort) evaluable participants at the follow-up time point [ADDRESS_1010595] 
cohorts, documented history of 13vPnC vaccination:
•Cohort 1:   Approximately 200 children ≥15 months to <24 months (<2 years) of age 
who have been previously vaccinated with at least 3 doses of 13vPnC.
•Cohort 2:   Approximately 200 children ≥2 years to <[ADDRESS_1010596] 3 doses of 13vPnC.
•Cohort 3:   Approximately 200 children ≥5 years to <10 years of age regardless of 
documentation of previous vaccination with 7vPnC or 13vPnC.
•Cohort 4:   Approximately 200 children ≥10 years to <18 years of age regardless of 
documentation of previous vaccination with 7vPnC or 13vPnC.
4.2. Scientific Rationale for Study Design
The purpose of this single-arm study is to provide safety and immunogenicity 
data in children in the setting of well-established national infant immunization programs with 7vPnC and subsequently with 13vPnC.  Similar studies were conducted with 13vPnC in a population of children in the setting of 7vPnC use showing 13vPnC was well tolerated and elicited an immune response to all 13vPnC serotypes.
73,74  Children ≥15 months of age to 
<5 years of age (Cohorts 1 and 2) will be eligible if they have been previously vaccinated with at least [ADDRESS_1010597] recent dose was received >2 months before enrollment. Children ≥5 to <18 years of age will be eligible regardless of previous 
vaccination status with 7vPnC or 13vPnC. Participants will be administered 1 dose of 20vPnC at Visit 1. This is consistent with the short-term catch-up recommendations by [CONTACT_159328] (ACIP) following 13vPnC introduction.  The recommendation was for a single dose of 13vPnC in children [ADDRESS_1010598] recent dose of 13vPnC, and it is consistent with the dosing series (1 dose) indicated for 13vPnC in unvaccinated children >2 years of age.
31CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 274.3.Justification for Dose
The 20vPnC candidate is modeled after 7vPnC and 13vPnC , and contains capsular 
polysaccharides from pneumococcal serot ypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 
14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F individually  conjugated to CRM 197.The vaccine 
is formulated to contain 2.[ADDRESS_1010599] y:
5.1.1. Cohort 1 and Cohort 2
Age and Sex:
1.Male or female children ≥15 months to < 5years of age at the time of consent .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010600] 2021
PFIZER CONFIDENTIAL
Page 28Type of Participant and Disease Characteristics:
2. Participants’ parent(s)/legal guardian(s) and participants, as age-appropriate, who are 
willing and able to comply with all scheduled visits and study procedures.
3. Healthy children determined by [CONTACT_13113], including medical history and 
clinical judgment, to be eligible for the study.
4. Expected to be available for the duration of the study and whose parent(s)/legal 
guardian(s) can be contact[CONTACT_739601].
5. Written documentation of receipt of at least [ADDRESS_1010601] been administered >2 months before enrollment into the study.
Informed Consent:6. Participants whose parent(s)/legal guardian(s) is capable of giving signed informed 
consent as described in Appendix 1 , which includes compliance with the requirements 
and restrictions listed in the informed consent document (ICD) and in this protocol.
5.1.2. Cohort 3 and Cohort 4
Age and Sex:
1. Male or female children ≥5 years to <18 years of age at the time of consent.
Type of Participant and Disease Characteristics:2. Participants’ parent(s)/legal guardian(s) and participants, as age-appropriate, who are 
willing and able to comply with all scheduled visits and study procedures.
3. Healthy children determined by [CONTACT_13113], including medical history and 
clinical judgment, to be eligible for the study.
4. Expected to be available for the duration of the study and whose parent(s)/legal 
guardian(s) can be contact[CONTACT_739601].
5. Negative urine pregnancy test for female participants who are menstruating.6. Female participant of childbearing potential or male participant able to father children 
who is willing to use a highly effective method of contraception as outlined in this protocol for at least [ADDRESS_1010602] if at risk of pregnancy with her/his partner; or female participant not of childbearing potential or male participant not able to father children.
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 29Informed Consent:
7. Participants whose parent(s)/legal guardian(s) is capable of giving signed informed 
consent as described in Appendix 1 , which i ncludes compliance with the requirements 
and restrictions listed in the I CD and in this protocol.  Depending on the age of the 
participant and according to local requirements, participants will also be asked to provide 
assent as appropriate (verbal or writ ten).
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
5.2.1. Cohort 1 and Cohort 2
Medical Conditions:
1.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg ,anaphy laxis) to any  component of the investigational product, or an y 
diphtheria toxoid –containing vaccine .
2.Significant neurological disorder or history  of seizure (excluding febrile seizure) or 
significant stable or evolving disorders such as cerebral pal sy, encephalopathy , 
hydrocephalus
,or other significant disorders.
3. Major known congenital malformation or serious chronic disorder.
4.History  of microbiologically  proven invasive disease caused by  [CONTACT_93293] .
5.Known or suspected immunodeficiency  or other conditions associated with 
immunosuppression, including, but not limited to, immunoglobulin class/subclass 
deficiencies, DiGeorge sy ndrome, generalized malignancy , human immunodeficiency  
virus (HIV) infection, leukem
ia, ly mphoma ,or organ or bone marrow transplant.
6. Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opi[INVESTIGATOR_871], contraindicate intramuscular injection.
7.Congenital, functional, or surgical asplenia.
8.Other acute or chronic medical or ps ychiatric condition including recent (within the past 
year) or active suicidal ideation or behavior or laboratory  abnormality  that may  increase 
the risk associated with study  participation or investigational product administr ation or 
may interfere with the interpretation of study results and, in the judgment of the 
investigator, would make the participant inappropriate for entry  into this study .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 30Prior/Concomitant Therapy:
9. Previous vaccination with any  investigational pneumococ cal vaccine or with PPSV23, or 
planned receipt through study  participation.
10.Currently receive s
treatment with immunosuppressive therap y, including cytotoxic agents 
or sy stemic corticosteroids, or planned receipt through the last blood draw.  If s ystemic 
corticosteroids have been administered short term (<14 day s) for treatment of an acute 
illness, participants should not be enrolled into the study  until corticosteroid therapy  has 
been discontinued for at least [ADDRESS_1010603] ration.  
Inhaled/nebulized, intra -articular, intrabursal, or topi[INVESTIGATOR_2855] (skin, ey es,or ears ) 
corticosteroids are permitted.
11.
Receipt of blood/plasma products or immunoglobulins (including hepatitis B 
immunoglobulin) or planned receipt through the last planned blood draw in the study  
(through Visit 2).
Prior/Concurrent Clinical Study Experience:
12.
Participation in other studies involving investigational drug(s), investigational vaccines, 
or investigational devices within 28 day s prior to study  entry  and/or during study  
participation.  Participation in purely  observational studies is acceptable.
Diagnostic Assessments:
Not applicable .
Other Exclusions:
13.Children or grandchildren who are direct descendants of investigat orsite staff members 
or [COMPANY_007] employ eeswho ar edirectl y involved in the conduct of the stud y.
5.2.2. Cohort 3 and Cohort 4
Medical Conditions:
1.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg ,anaphy laxis) to any  component of the investigational product, or an y 
diphtheria toxoid –containing vaccine .
2.Significant neurological disorder or history  of seizure (excluding febrile seizure) or 
significant stable or evolving disorders such as cerebral palsy , encephalopathy , 
hydrocephalus
,or other significant disorders.
3. Major known congenital malformation or serious chronic disorder.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 314.History  of microbiologically  proven invasive disease caused by  [CONTACT_93293] .
5.Known or suspected immunodeficiency
 or other conditions associated with 
immunosuppression, including, but not limi ted to, immunoglobulin class/subclass 
deficiencies, DiGeorge sy ndrome, generalized malignancy , HIV infection, leukemia, 
lymphoma , or organ or bone marrow transplant.
6. Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opi[INVESTIGATOR_871], contraindicate intramuscular injection.
7.Congenital, functional, or surgical asplenia.
8.Other acute or chronic medical or ps ychiatric condition including recent (within the past 
year) or active suicidal ideation or behavior or laboratory  abnormality  that may  increase 
the risk associated with study  participation or investigational product administration or 
may interfere with the interpretation of study results and, in the judgment of the 
investigator, would make the participant i nappropriate for entry  into this study .
9.Pregnant or breastfeeding female participants.
Prior/Concomitant Therapy:
10. Previous vaccination with any  investigational pneumococcal vaccine or with PPSV23, or 
planned receipt through study  participation.
11.Currently receives treatment with immunosuppressive therap y, including cytotoxic agents 
or sy stemic corticosteroids, or planned receipt through the last blood draw.  If s ystemic 
corticosteroids have been administered short term (<14 day s) for treatment of an acute 
il
lness, participants should not be enrolled into the study  until corticosteroid therapy  has 
been discontinued for at least [ADDRESS_1010604] administration.  
Inhaled/nebulized, intra -articular, intrabursal, or topi[INVESTIGATOR_2855] (skin, eyes,or ea rs) 
corticosteroids are permitted.
12. Receipt of blood/plasma products or immunoglobulins (including hepatitis B 
immunoglobulin) or planned receipt through the last planned blood draw in the study  
(through Visit 2).
Prior/Concurrent Clinical Study Experience:
13. Participation in other studies involving investigational drug(s), investigational vaccines, 
or investigational devices within 28 day s prior to study  entry  and/or during study  
participation.  Participation in purely  observational studies is acceptable.
Diagnostic Assessments:
Not applicable.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 32Other Exclusions:
14.Children or grandchildren who are direct descendants of investigat orsite staff members 
or [COMPANY_007] employ ees who are directl y involved in the conduct of the stud y.
5.3.Lifestyle Considerations
5.3.1. Contraception (If Applicable)
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitte d list of contraception methods
(Section 10.4) and will confirm that the participant has been instructed in its consistent and 
correct use.  At time points indicated in the SoA, the investigator or designee will inform the 
participant of the need to use highl y effective contraception consistentl y and c orrectly
 and 
document the conversation and the participant’s affirmation in the participant’s chart 
(participants need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception).  In addition, the investigator or des ignee will instruct the 
participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants whose parent(s)/le gal guardian(s) have consented 
for them to participate in the clinical study  but are not subsequently  assigned to 
investigational product
.  A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure participan ts to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries from 
regulatory  authorities.  Minimal information includes demography , screen failure details, 
eligibility  criteria, and any  AE or SAE recorded from signing the informed consent until the 
time of determination of screen failure.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  
not be rescreened.
5.5.Temporary Delay Criteria
The following conditions ar e temporary  or self -limiting and a participant may  be vaccinated 
and/or have blood drawn in the study  once the condition(s) has/have resolved and no other 
exclusion criteria are met.
The blood draw prior to vaccination should take place on the same day  as the vaccination.
5.5.1. Criteria for Temporarily Delaying Vaccine Administration 
Current febrile illness (body  temperature ≥38.0°C [ ≥100.4°F]) or other acute illness 
within [ADDRESS_1010605] administration.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010606] 2021
PFIZER CONFIDENTIAL
Page 33•Receipt of short-term (<14 days) systemic corticosteroids. Investigational product 
administration should be delayed until systemic corticosteroid use has been discontinued for at least 28 days.  Inhaled/nebulized, intra-articular, intrabursal, or topi[INVESTIGATOR_2855] (skin or eyes) corticosteroids are permitted.
5.5.2. Criteria for Temporarily Delaying Immunogenicity Blood Draw
•Receipt of antibiotic therapy within 72 hours before blood draw. Topi[INVESTIGATOR_634665].
6. STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.
For the purposes of this protocol, the term investigational product may be used 
synonymously with study intervention.
6.1. Study Intervention(s) Administered
20vPnC is a sterile liquid suspension formulation containing saccharides from pneumococcal 
serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F individually conjugated to CRM
197.  
 
Investigational product will be supplied by [CONTACT_407394].  Each syringe will be 
packaged in a carton with a label and a tamper-evident seal, and will be labeled as required per country requirement (refer to the investigational product manual [IP manual]).
6.1.1. Administration
All participants will receive a single dose of 20vPnC at Visit 1.
The 0.5-mL dose of 20vPnC will be administered intramuscularly into the left leg (option for 
Cohort 1 only) or left arm by a designated site staff member. All other vaccinations (if given) should be administered into a limb other than the site of 20vPnC injection.  The location of the injection of each vaccine administered (investigational product and other) will be recorded.
Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute hypersensitivity reaction should be available in accordance with local guidelines for standard immunization practices.CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010607] 2021
PFIZER CONFIDENTIAL
Page 34Administration of investigational products should be performed by [CONTACT_407395], Good Clinical Practice (GCP)-trained, and vaccine-experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by [CONTACT_5737], state, and institutional guidance.
Investigational product administration details will be recorded on the case report form (CRF).6.1.2. Medical Devices
In this study, medical devices being deployed are the 20vPnC prefilled syringes.
Instructions for medical device use are provided in the IP manual.Medical device deficiencies, including those resulting from malfunctions of the device, must 
be detected, documented, and reported by [CONTACT_23528]. Please refer toSection 8.3.9 for details.
6.2. Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study interventions received and any discrepancies are reported and resolved before use of the study intervention, as applicable for temperature-monitored shipments.
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010608] should be prepared and dispensed by [CONTACT_110444] (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as allowed by [CONTACT_5737], state, and institutional guidance.CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 366.3.Measures to Minimize Bias: Randomization and Blinding
Since all participants will receive 20vPnC at Visit 1, this will be an open -label vaccination 
and will be prepared and administered by  a site staff member or designee.
6.3.1. Allocation to Study Intervention
Laboratory  personnel performing the immunologic assay s will be blinded to the visit 
information until all assays have been completed and assay  results finalized.
Each participant will receive a single dose of 20vPnC; however, the investigational product 
will be assigned using an interact ive response technology  (IRT)system (interactive 
Web -based response [I WR]) .  The site personnel (study  coordinator or specified designee) 
will be required to enter or select information including but not limited to the user’s 
identification (ID) and passw
ord, the protocol number, and the participant number.  The site 
personnel will then be provided with a dispensable unit (DU) or container number when 
investigational product is being supplied via the IRT sy stem .  The IRT s ystem will provide a 
confirmation report containing the participant number and DU or container number 
assigned. The confirmation report must be stored in the site’s files.
The study -specific I RT reference manual and I P manual will provide the contact [CONTACT_19974] s ystem.
6.4. Study Intervention Compliance
All doses of investigational product will be administered by  [CONTACT_110443].
6.5.Concomitant Therapy
6.5.1. Prohibited Concomitant Vaccines and Treatments 
Receipt of an y investigational vaccines, drugs, or medical devices is prohibited during 
study  participation.
Receipt of nonstudy  pneumococcal vaccine is prohibited during study  participation.
Receipt of blood/plasma products, immunoglobulins, and/or immunosuppressive therap y 
(including a ≥14- day course of s ystemic corticosteroids) is prohibited through Visit 2.
6.5.2. Permitted Concomitant Vaccines and Treatments
Influenza vaccine is permitted at any  time during influenza season in this study .  
Howev er, if feasible, it isrecommended that influenza vaccine be administered at least 
14days before or
after 20vPnC administration.
Receipt of quadrivalent meningococcal conjugate vaccine is permitted only  after the 
blood sample is collected at Visit 2.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 37Receipt of other licensed nonstudy  vaccines (except pneumococcal vaccine as described 
above) is permitted.   However, if feasible, it isrecommended that licensed nonstudy  
vaccines be administered at least 14 day s (for nonlive vaccines) or at least 28 day s 
(for live vaccines) before or
after 20vPnC administration.
Use of topi[INVESTIGATOR_634666].
The use of proph ylactic antipy retic/pain medication, while permitted, is not 
recommended on the day of investigational product administration (before orafter 
vaccination) .
Inhaled/nebulized, topi[INVESTIGATOR_2855] (skin, ey es, or ears), or localized injections of corticosteroids 
(eg, intra -articular or intrabursal administration) are permitted during participant 
participation in the study .
Prescription and nonprescription medications, vitamins, minerals, and herbal remedies 
are permitted during the study .
6.5.3. Recording Prior and Concomitant Vaccines and Treatments
The name , location ,and date of administration for any  nonstudy  vaccinations received from 
the time of signing of t he ICD to Visit [ADDRESS_1010609] recent ( third or fourth) dose of [ADDRESS_1010610] 
recent dose of 7vPnC or 13vPnC will be recorded on the CRF, if available.
Only  medications taken to treat SAEs or NDCMCs from the time of signing of the ICD to the 
final visit (approximately  6 months after vaccination at Visit 1) will be collect and recorded 
in the CRF.
6.6.
Dose Modification
Not applicable.
6.7.Intervention After the End of the Study
No intervention will be provided to study participants at the end of the study .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 387. DISCONT INUATION OF STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Since this is a single -dose study , this section is not applicable.
7.2.Participant Discontinuation/Withdrawal From the Study
A participant may  be wi thdrawn from the study  at any  time at the request of his/her own 
parent(s)/legal guardian(s), or may  be withdrawn at any  time at the discretion of the 
investigator for safet y, behavioral, compliance, or administrative reasons.
If a participant does not ret urn for a scheduled visit, every  effort should be made to contact 
[CONTACT_2299] ’s parent(s)/legal guardian(s).  All attempts to contact [CONTACT_2299] ’s 
parent(s)/legal guardian(s) and information received during contact [CONTACT_407399]
’s source document.   In any circumstance, every  effort should 
be made to document participant outcome, if possible.
At the time of discontinuing, please refer to the investigator s ite file(ISF)and SoA for 
assessments to be collected at the time of stud y discontinuation and follow -up and for an y 
further evaluations that need to be completed.
The p articipant ’s parent(s)/legal guardian(s) should ideally  notify  the investig ator in writing 
of the deci sion to withdraw consent from future follow -up, whenever possible. The 
participant ’sparent(s)/legal guardian(s) should be questioned regarding their reason for 
withdrawal. The investigator or his or her designee should capture the reason for withdrawal 
in the CRF for all participants.
The participant should be requested to return for a final visit, if applicable, and the 
investigator will perform the procedures indicated for the next visit. Any AEs or SAEs that 
are continuing at the time of withdrawal from the study  should be followed until resolution 
or
, in case of permanent impairment, until the condition stabilizes.
A final telephone contact 6 months after vaccination ( Section 8.10.3 ) for the collection of 
safet y information should be completed for all participants who withdraw or who have been 
withdrawn after administra tion of investigational product, unless consent for further contact 
[CONTACT_346263], or the participant is lost to follow-up. Participant withdrawal should be 
explained in the source documents and should include whether the withdrawal is from study  
procedures and/or post vaccination study  follow -up.
If a participant is withdraw n from the stud y, his/her parent(s)/legal guardian(s) may request 
destruction of an y remaining samples, but data alread y generated from the samples will 
continue to be available, a nd may  be used to protect the integrity  of existing anal yses.
The 
investigator must document an y such requests in the site study records.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 39If the participant iswithdraw nfrom the study  and his/her parent(s)/legal guardian(s) also 
withdraws consent for disclosure of future information, no further evaluations should be 
performed and no additional data should be collected. The sponsor may  retain and continue 
to use an y data collected before such withdrawal of consent.
When a par ticipant iswithdraw nfrom the study  because of an SAE, the SAE must be 
recorded on the CRF and reported on the Vaccine SAE Report ing Form .
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol devia tions so long as the participant ’s safet y was preserved.
7.3.Lost to Follow -up
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and the participant’s parent(s)/legal guardian(s) is unable to be con tacted b y 
the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit or fails to respond to the 6- month safety  follow -up telephone call :
The site must attempt to contact [CONTACT_2299]’s parent(s)/legal guardian(s) and 
reschedule the missed visit as soon as possible and counsel the participant’s 
parent(s)/legal guardian(s) on the importance of maintaining the assigned visit schedule 
and ascertain whether or not the participant’s parent(s)/legal guardian(s) wishes the 
participant to,and/or should , continue in the study;
Before a participant is deemed lost to follow- up, the investigator or designee must make 
every  effort to regain contact [CONTACT_6635]’s parent(s)/legal guardian(s) 
(wherepossible, 3 telephone calls and, if necessary , a certified letter to the participant’s 
last known mailing address or local equivalent methods).  These contact [CONTACT_97254]’s medical record;
Should the participant’s parent(s)/legal guardian(s) continue to be unreachable, the 
participant will have been considered to have withdrawn from the study .
Discontinuation of specific sites or of the study  as a whole is handled as part of Appendix 1 .
8. STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.
Study  procedures and their timing are summarized in the SoA.  Protocol waivers or 
exemptions are not allowed.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 40Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue study  
intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria.  The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as de scribed.  However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the sa fety and 
well-being of the participant.  When a protocol- required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes a re adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
In the case of extreme circumstances, such as natural disasters or a pandemic, visits for 
follow -up or procedures may  need to be conducted through other means (eg, telephone, home 
visits).
8.1.Efficac y Assessments
8.1.1. Immunogenicity Assessments
Blood samples ( Cohort s 1 and 2: approximately  5mL per sample ; Cohort s 3 and 4: 
approximately  10 mL per sample) will be collected from all participants prior to vaccination 
at Visit 1 and at Visit 2 (1 month after vaccination).  These are the immunogenicity  time 
points.
The total blood sampling volume for individual participants in this study  is approxi mately  
10mL in children ≥15 months to <5 y ears of age ( Cohort s 1 and 2) , and 20 mL  in children 
and adolescents ≥5 to <18 y ears of age (
Cohort s 3 and 4).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010611] 2021
PFIZER CONFIDENTIAL
Page 41Pneumococcal Responses
IgG Responses to the 20 Pneumococcal Serotypes Contained in 20vPnC
IgG antibody concentrations for serotypes present in 20vPnC (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 
10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) will be determined on all sera collected at the 2 immunogenicity time points (Visits 1 and 2).  The serotype-specific IgG concentrations will be measured by [CONTACT_4618]’s multiplex Luminex immunoassay.
OPA Responses to the 20 Pneumococcal Serotypes Contained in 20vPnC
OPA titers for serotypes present in 20vPnC (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 
15B, 18C, 19A, 19F, 22F, 23F, and 33F) will be determined in randomly selected subsets of sera for the immunogenicity time points (Visits 1 and 2). These subsets will be randomlyselected, by [CONTACT_739602], to ensure that each subset has equal representation ofboth vaccine groups. Further details will be described in the clinical specimen assessment plan (CSAP).  The serotype-specific OPA titers will be measured by [CONTACT_4618]’s OPA assay.
 
 
8.1.2. Biological Samples
Blood samples will be used only for scientific research.  Each sample will be labeled with a 
code so that the laboratory personnel testing the samples will not know the participant’s identity.  Samples that remain after performing assays outlined in the protocol may be stored by [CONTACT_4618].  Unless a time limitation is required by [CONTACT_240846], the samples will be stored for up to 15 years after the end of the study and then destroyed.  
 
 No testing of the participant’s genetic material will be performed.
The participant’s parent(s)/legal guardian(s) may request that the participant’s samples, if 
still identifiable, be destroyed at any time (depending on the age of the participant and according to local requirements, participants may also request that their samples be
destroyed); however, any data already collected from those samples will still be used for this 
research. The biological samples may be shared with other researchers as long as confidentiality is maintained and no testing of the participant’s genetic material is performed.C
CICCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 428.2.Safety Assessments
A clinical assessment, including medical history  and measurement of temperature as 
appropriate for the age of the child, according to routine local practice will be performed on 
all participants prior to vaccination to determine participant eligibility  and to establish a 
clinical baseline.  Significant medical history  and significant findings from any  physical 
examination (if performed) will be recorded as medical history  in the CRF.  Temperature 
measurement prior to vaccination will be documented and recorded in the CRF.
The participant will be observed for 30 minutes after study  vaccination and any  reactions 
during the visit will be assessed and recorded.
Prompted e -diary  events, including local reactions (redness, swelling, and pain at the 
injection site ) and sy stemic events (
Cohort 1: fever, decreased appetite, drowsiness/increased 
sleep, and irritability ; Cohorts 2- 4: fever, fatigue, headache, muscle pain, and joint pain ) that 
occur within 7days following investigational product administration (Day s 1 to 7, where 
Day 1 is the day  of vaccination) are graded as described in Section 8.2.2 .  Furthermore, AEs, 
SAEs, and NDCMCs will be collected as defined in Section 10.3.
Planned time points for all safety  assessments are provided 
in the SoA.  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  concerns.
8.2.1. Participant Electronic Diary
The participant’s parent(s)/legal guardian(s) will be asked to monitor and record l ocal 
reactions, specific s ystemic events, fever, and antipy retic/pain medication taken for 7 day s, 
each evening following the study  vaccination using an e -diary  (in a provisioned device or 
application on a personal device). This allows recording of these assessments only  within a 
fixed time window, thus providing an accurate representation of the participant’s experience.  
Data on local reactions, specific s ystemic events, fever, and use of antipy retic/pain 
medication reported in the e -diary  will be transf erred electronicall y to the e -diary  vendor, 
where they  will be available for review by  [CONTACT_431], their qualified designees, and 
sponsor staff at all times via an internet -based portal.  At intervals agreed to by  [CONTACT_240847], these data will be transferred electronically  to [COMPANY_007] for anal ysis and reporting.
The daily  e-diary  data will not be captured in the CRF.  However, if a participant is 
withdrawn because of prompted events reported in the e- diary , the event(s) should be 
recorded on the A E page of the CRF, regardless of whether the investigator considers the 
event(s) to be clinically  significant.
The investigator or designee must obtain stop dates for an y local reactions orspecific 
systemic events ongoing on the last day  that the e -diary  was completed.  The stop dates 
should be entered in the CRF.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 43Investigators (or an appropriately  qualified designee) are required to review the e -diary  data 
online at frequent intervals (daily  is optimal) to evaluate participant compliance and reported 
even ts as part of the ongoing safet y review.
8.2.2. Grading Scale for Prompted Events
The grading scales used in this study  to assess prompted events as described below are based 
on concepts outlined in the Food and Drug Administration (FDA) Center for Biologics 
Evaluation and Research (CBER) guidelines on toxicity  grading scales for adults and 
adolescent volunteers enrolled in preventive vaccine clinical trials ,75buthave been adapted 
for applicabilit y to healthy infants.
[IP_ADDRESS]. Local Reactions
For the first 7 days following the stud y vaccination (Day s 1 through 7, where Day  1 is the 
day of vaccination), the participant’s parent(s)/legal guardian(s) will be asked to assess 
redness, swelling, and pain at the injection site (left leg [option for Cohort 1 only ]or left 
arm) and to record the symptoms in the e -diary  in the evening.  Redness and swelling will be 
measured and recorded in measuring device (caliper) units (range: 1 to >14; an entry  in the 
e-diary  of 15 will denote >14), and then categorized during anal ysis as mild, moderate, or 
severe based on the grading scales in Table 1 below.  Measuring device units can be 
converted to centimeters according to the following scale: 1 measuring device unit = 0.5 cm.  
Pain at the vaccine injection site will be assessed by  [CONTACT_941] p articipant’s parent(s)/legal 
guardian(s) as mild, moderate, or severe according to the grading scale sin Table 1 below.  
The participant’s parent(s)/lega l guardian(s) will be prompted to contact [CONTACT_739603] a severe (Grade 3 or above) local reaction to assess the reaction 
and perform an unscheduled assessment or visit as appropriate.
Only  an investigator is able to class ify a participant’s local reaction as Grade 4, after ph ysical 
examination of the participant or documentation from another medicall y qualified source 
(eg, emergency  room or hospi[INVESTIGATOR_8735]).  If a participant experiences a Grade [ADDRESS_1010612] immediately  notify  the sponsor. Site staff will educate the 
participant’s parent(s)/legal guardian(s) regarding signs and s ymptoms that would prompt 
site contact.
The procedure for notification of the sponsor is provided in the ISFor equiva lent.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 44Table 1. Grading Scales for Local Reactions in Study Participants
Local Reaction GRADE 1
MildGRADE 2 
ModerateGRADE 3a
SevereGRADE 4b
Redness 1 to 4 caliper units
(or measuring device 
units)
=
>0 to 2.0 cm5 to 14 caliper units
(or measuring device 
units)
=
>2.0 to 7.0 cm>14 caliper units 
(or measuring device 
units)
=
>7.0cmNecrosis or 
exfoliative 
dermatitisb
Swelling 1 to 4 caliper units
(or measuring device 
units)
=
>0 to 2.0 cm5 to 14 caliper units
(or measuring device 
units)
=
>2.0 to 7.0 cm>14 caliper units 
(or measuring device 
units)
=
>7.0cmNecrosisb
Pain at injection site 
(tenderness)Cohort 1: Hurts if 
gently touched
(eg,whimpers, 
winces, protests ,or 
withdraws)
Cohort s 2-4:  Does 
not interfere with 
activityCohort 1: Hurts if 
gently touched with 
crying
Cohort s 2-4: 
Interfere swith 
activityCohort 1: Causes 
limitation of limb 
movement
Cohort s 2-4: 
Prevents daily 
activitycEmergency room 
visit or 
hospi[INVESTIGATOR_407370] 
(tenderness) at 
injection site
Abbreviations: CRF = case report form; e -diary = electronic diary.
Note: If the size of the redness and/or swelling falls between 2 measuring device units, the higher measuring 
device unit number will be recorded in the e -diary.
a.Parent(s)/legal guardian(s) of the participants experiencing local reactions >14 caliper units (>7.0 cm) are 
to be contact[CONTACT_9298]. An unscheduled visit may be required.
b.Grade 4 assessment should be made by [CONTACT_093]. Grade 4 w ill not be collected in the e -diary but 
will be collected as an AE in the CRF. The severity of the local reaction should be graded using the AE 
grading scale in Section 10.3.4 .
c.Prevents daily activity, eg, results in missed days of work or school or is otherwise incapacitating .
[IP_ADDRESS]. Systemic Events –Symptoms and Fever
[IP_ADDRESS].1. Symptoms
For the first 7 day s following the stud y vaccination (Day s 1 through 7, where Day  1 is the 
day of vaccination), the participant’s parent(s)/legal guardian(s) will be asked to assess
decreased appetite, drowsiness/increased sleep, and irritability  in Cohort [ADDRESS_1010613] the sy mptoms in 
the e -diary  (in a provisioned device or application on a personal device) in the evening.  The 
symptoms will be assessed by  [CONTACT_2299]’s parent(s)/legal guardian(s) as mild, moderate, 
or severe according to the grading scale sin Table 2and Table 3 below.  The participant’s 
parent(s)/legal guardian(s) will also be instructed to contact [CONTACT_739604] 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 45experiences an y possible Grade 4 prompted s ystemic event (ie, emergency room visit or 
hospi[INVESTIGATOR_407371], severe drowsiness/increased sleep, or severe 
irritability ) for [ADDRESS_1010614] the participant’s 
parent(s)/legal guardian(s) to obtain additional information on Grade 3 events entered into 
the e -diary .
Only  an investigator is able to classify  a participant’s sy stemic event as Grade 4, after 
physical examination of the participant or documentation from another medically  qualified 
source (eg, emergency  room or hospi[INVESTIGATOR_8735]) or telephone contact [CONTACT_6635]’s 
parent(s)/legal guardian(s).  If a participant experiences a Grade [ADDRESS_1010615] immediately  notify  the sponsor.
The procedure for notification of the sponsor is provided in the study  reference manual
(SRM )or equivalent.
Table 2. Grading Scales for Systemic Events -Participants Who Are ≥15Months to 
<2 Years of A ge (Cohort 1)
Systemic Event GRADE 1
MildGRADE 2 
ModerateGRADE 3
SevereGRADE 4a
Decreased appetite 
(loss of appetite)Decreased interest in 
eatingDecreased oral 
intakeRefusal to feed Emergency room visit 
or hospi[INVESTIGATOR_383784] (loss of 
appetite)
Drow siness
(increased sleep )Increased or 
prolonged sleepi[INVESTIGATOR_634669] 
(increased sleep)
Irritability
(fussiness)
(synonym ouswith 
restless sleep; 
decreased sleep)Easily consolable Requiring 
increased 
attentionInconsolable; 
crying cannot 
be comfortedEmergency room visit 
or hospi[INVESTIGATOR_383787] 
(fussiness)
Abbreviation s: CRF = case report form; e -diary = electronic diary.
a.Grade 4 assessment should be made by [CONTACT_093]. Grade 4 w ill not be collected in the e -diary but 
willbe collected as an AE in the CRF. The severity of the systemic event should be graded using the AE 
severity grading scale provided in Section 10.3.4 .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 46Table 3. Grading Scales for Systemic Events -Participants Who Are ≥2 to 
<18 Years of A ge (Cohort s 2 -4)
Systemic Event GRADE 1
MildGRADE 2 
ModerateGRADE 3
SevereaGRADE 4b
Fatigue
(=tiredness in 
diaries)Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room visit 
or hospi[INVESTIGATOR_739589]: CRF = case report form; e -diary = electronic diary.
a.Prevents daily routine activity, eg, results in missed days of work or school or is otherwise incapacitating; 
includes use of narcotics for analgesia.
b.Grade 4 assessment should be made by [CONTACT_093]. Grade 4 w ill not be collected in the e -diary but 
will be collected as an AE in the CRF. The severity of the systemic event should be graded using the AE 
severity grading scale provided in Section 10.3.4 .
[IP_ADDRESS].2. Fever
In order to record information on fever, a digital thermometer will be given to the 
participant’s parent(s)/legal guardian(s) with instructions on how to measure temperature at 
home.  Temperature will be collected in the evening ,daily,for 7 day s following the study  
vaccination (Day s 1 through 7, where Day  1 is the day  of vaccination) and at any  time during 
the 7 day s that fever is suspected.  Fever is defined as a temperature of ≥38.0 °C (≥ 100.4°F).  
The highest temperature for each day  will be recorded in the e -diary .  In the event of a fever 
on Day  7, temperature will be collected dail y until fever has resolved (1 d ay of temperature 
less than 38.0 °C [100.4 °F]) in order to collect a stop date in the CRF.  A participant’s 
parent(s)/legal guardian(s) will be prompted to contact [CONTACT_634683] a fever >40.0
°C (>104.0°F) to assess the feve r and perform an unscheduled 
assessment , as applicable (see Section 8.10.4) .  Study  staff may  also contact [CONTACT_2299]’s 
parent( s)/legal guardian(s) to obtain additional information if a temperature of >38.9 °C 
(>102 .0°F) is entered into an e- diary .  Temperature will be measured and recorded to 
1decimal place and then grouped into ranges for the anal ysis; see Table 4below.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 47Table 4. Ranges for Fever
≥38.0 °C to 38.4 °C
>38.4 °C to 38.9 °C
>38.9 °C to 40.0 °C
>40.0 °C
Note: Fever is defined as temperature ≥38.0°C.
[IP_ADDRESS]. Use of Antipyretic/Pain Medication
The participant’s parent(s)/legal guardian(s) will be asked to record the use of 
antipy retic/pain medication (y es/no) in the e -diary (in a provisioned device or application on 
a personal device) in the evening, daily,for 7 day s following vaccination, where Day  1 is the 
day of vaccination.
8.2.3. Clinical Safety Laboratory Assessments
Clinical safety  laboratory tests are not required by  [CONTACT_3181].
If laboratory  values from non–protocol -specified laboratory  assessme nts performed at the 
institution’s local laboratory  require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
8.2.4. Pregnancy Testin g (If Applicable)
Urine pregnancy  tests will have a sensitivity  of at least 25 mIU/mL .  Pregnancy  tests will be 
performed in wom en of childbearing potential (WOCBP) at the times listed in the SoA, 
immediately  before the administration of the vaccine. A ne gative pregnancy  test result will 
be required prior to the participant ’sreceiving the investigational product.  Pregnancy  tests 
may also be repeated if requested by  [CONTACT_110453] (IRBs)/ethics committees 
(ECs) or if required b y local regulat ions. In the case of a positive confirmed pregnancy , the 
participant will be withdrawn from administration of investigational product and from the 
study .
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs will be reported b y the participant’s parent(s)/legal guardian(s).
Events that, in the clinical judgment of the investigator, are 1) consistent with normal growth 
and development and 2) do not differ significantly in frequency  or severity  from expected ,
are not generall y to be considered adverse events. Examples may  include, but are not limited 
to, teething, contact [CONTACT_407422], spi[INVESTIGATOR_322054], colic, or ty pi[INVESTIGATOR_407372]/cry ing in infants and 
children.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 48The investiga tor and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether i t 
meets the criteria for classification as an SAE or caused the participant to discontinue from 
the study  (see Section 7).
Each parent /legal guardian will be questioned about the occurrence of AEs in a nonleading 
manner .In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific 
follow -up information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant’s parent(s)/legal guardian(s) 
provides informed consent, which is obtained before the participant’s participation in the 
study  (ie, before undergoing an y stud y
-related procedure and/or receiving investigational 
product), through and including Visit 2.  At Month 6 (final telephone contact), the 
participant ’sparent(s)/legal guardi an(s) will be contact[INVESTIGATOR_530] b y telephone to collect information 
about SAEs, including hospi[INVESTIGATOR_739590] , since Visit 2.
Follow -up by  [CONTACT_739605] a level acceptable to the investigator, and 
[COMPANY_007] concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant is withdr awn from the study  and their parent(s)/legal guardian(s) also 
withdraws consent for the collection of future information, the active collection period ends 
when consent is withdrawn.
If a participant definitively  discontinues or temporarily  discontinues study  intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the Vaccine SAE Report ingForm.
Investigators are not obligated to activel y seek AEs or SAEs after conclusion of the study  
participation .  However, i f the investigator learns of an y SAE, including a death, at an y time 
after a participant has completed o
rwithdrawn early  from the study , and he/she considers the 
event to be reasonabl y related to the study  intervention or study  participation, the investig ator 
must promptly  notify  the sponsor.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period are reported to [COMPANY_007] 
Safety  on the Vaccine SAE Report ingForm i mmediatel y upon awareness and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3 .  The investigator will 
submit any  updated SAE data to the sponsor within 24 hours of it being available.
SAEs occurrin g in a participant after the active collection period has ended are reported to 
[COMPANY_007] Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to invest igational 
product must be reported to [COMPANY_007] Safety .
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_1010616] on the CRF all directly  observed and all 
spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant’s parent(s)/legal guardian(s) is the preferred 
method to inquire about AE occur rences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts.  For each event, the investigator must pursue and 
obtain adequate information until resolu tion, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomit ant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety .
Further information on follow -up procedures is given in Appendix 3 (Section 10.3).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 508.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_739606] t hat legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and othe r 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.  The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) according to local regulatory  requirements and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety  report describing an SAE or other 
specific safet y information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the IBand will notify  the I RB/EC, if appropriate according to local 
requirements.
8.3.5. Exposure Duri ng Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure Dur ing Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention.
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception.
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure.  Below are examples of 
environmental exposure during pregnancy :  
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_78262], inhalation, or skin 
contact.
A male famil y member or healthcare provider who has been exposed to the study 
intervention by [CONTACT_78262], inhalation, or ski n contact [CONTACT_240854].

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 51The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred.  The initial information su bmitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy).
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety on the Vaccin e SAE Report ingForm and an EDP 
Supplemental Form, regardless of whether an SAE has occurred.   Details of the 
pregnancy  will be collected after the start of study  intervention and until study  end.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the 
Vaccine SAE Reporting Form and EDP 
Supplemental Form.  Since the exposure information does not pertain to the 
participant enrolled in the study , the information is not recorded on a CRF; howe ver, 
a cop y of the completed Vaccine SAE Reporting Form is maintained in the 
investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -
up to the initial EDP Supplemental Form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs.  If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs.  Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_1010617] 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention.
Additional information regarding the EDP may  be requested by  [CONTACT_456].  Further 
follow -up of birth outcom es will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 52Form to delive r to his partner.  The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure).  An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_19991].
The investigator must report exposure dur ing breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred.  The 
information must be reported using the Vaccine SAE Reporting Form.  When exposure 
during breastfeeding occurs in the setti ng of environmental exposure, the exposure 
information does not pertain to the participant enrolled in the study , so the information is not 
recorded on a CRF.  However, a cop y of the completed Vaccine SAE Reporting Form is 
maintained in the investigator si te file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use.  However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the Vaccine SAE Report ingForm, regardless of whether there is an 
associated SAE.  Since the information does not pertain to a participant enrolled in the study , 
the information is not recorded on a CRF; however, a cop y of the completed Vaccine SAE
Report ingForm is maintained in the ISF
.
8.3.6. Cardiovascular and Death Events
Not applicable

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 538.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable
8.3.8. Adverse Events of Special Interest
Not applicable
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population .
8.3.9. Medical Device Deficiencies
Medical devices are being provided for use in this study  for the purposes of administering the 
investigational product
.  In order to fulfill regulatory reporting obligati ons worldwide, the 
investigator is responsible for the detection and documentation of events meeting the 
definitions of deficiencies that occur during the study  with such devices.
The definition of a medical device deficiency can be found in Appendix 8 .
NOTE: Deficiencies fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Section 8.3.3 andSection 10.3 of the protocol.
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies or malfunctions of the device that result in an incident will be 
detected, documented, and reported during all periods of the study  in which the medical 
device is used.
If the investigator learns of an ydevice deficiency at an y time after a participant has been 
discharged from the study, and such incident is considered reasonabl y related to a m edical 
device provided for the study , the investigator will promptly  notify  the sponsor.
The method of documenting medical device deficiencies is provided in Appendix 8 .
[IP_ADDRESS]. Follow -up of Medical Device Deficiencies
All medical device deficiencies involving an AE will be followed and reported in the same 
manner as other AEs (see Section 8.3.3). This applies to all participants, including those who 
discontinue study  intervention. The investigator is responsible for ensuring that follow -
up 
includes an y supplemental investigations as indicated to elucidate the nature and/or causalit y 
of the deficiency .
New or updated information will be recorded on a follow -upform with all changes signed 
and dated b y the investigator.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Prompt Reporting of Device Deficiencies to Sponsor
Device deficiencies will be reported to the sponsor within [ADDRESS_1010618] be reported to [COMPANY_007] Safet y 
within 24 hours upon the investigator’s awareness as outlined in Section [IP_ADDRESS] and 
Section [IP_ADDRESS].
The sponsor will be the contact [CONTACT_227989].
Information will be provided to the sponsor as described in the IP manual.
[IP_ADDRESS]. Regulatory Reporting Requirements for Medical Device Deficiencie
s
The investigator will promptly  report all device deficiencies occurring with any  medical 
device provided for use in the study in order for the sponsor to fulfill the legal responsibility  
to notify  appropriate regulatory  authorities and other entities about certain safet y information 
relating to medical devices being used in clinical studies.
The investigator, or responsible person according to local requirements (eg, the head of the 
medical institution), will comply  with the applicable local regulatory  requ irements relating to 
the reporting of device deficiencies to the IRB/EC.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong participant, or at the wrong time, or at the wrong do sage strength.
Exposures to the investigational product under study  may  occur in clinical trial settings, such 
as medication errors.
Safety Event Recorded on the CRF Reported on the Vaccine SAE Report ing
Form  to [COMPANY_007] Safety Within 24 Hours of 
Awareness
Medication errors All (regardless of whether 
associated with an AE)Only if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do or 
do not involve the study  participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 55In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within 24 hours on a Vaccine SAE
Report ingForm only when associated with an SAE .
Other examples include, but are not limited to:
The administration of expi[INVESTIGATOR_149325];
The administration of an incorrect investigational product;
The administration of an incorrect dosage;
The administration of investigational product that has undergone temperat ure excursion 
from the specified storage range, unless it is determined by [CONTACT_346268].
8.4.Treatment of Overdose
For this study , any  dose of investigational product greater than [ADDRESS_1010619] within a 24 -hour time period will be considered an overdose.
[COMPANY_007] does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_22840] 24 hours .
2.Closely  mon itor the participant for an y AEs/SAEs.
3.Document the quantit y of the excess dose as well as the duration of the overdose in the 
CRF.
4.Overdose is reportable to Safety  only when associated with an SAE .
8.5.Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study .
8.6.Pharmacodynamics
Pharmacod ynamic parameters are not evaluated in this study .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 568.7.Genetics
Genetics (specified anal yses) are not evaluated in this study .
8.8.Biomarkers
Biomarkers are not evaluated in this study .
8.9.Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study .
8.10. Study Procedures
The study  procedures are summarized in the SoA (Section 1.3). The day  of Dose [ADDRESS_1010620] some flexibility .
8.10.1. Visit 1 (Vaccination 1, Day 1)
Prior to vaccination:
Obtain a personally  signed and dated ICD indicating that the participant’s parent(s)/legal 
guardian(s) has been informed of all pertinent aspects of the study  before performing any  
study -specific procedures.
Assign a participant number via the IRT.
Obtain and record the participant’s demographic information (including date of birth, sex, 
race,and ethnicit y). The complete date of birth (ie, DD -MMM -YYYY) will be collected 
as permitted per local regulations to critically  evaluate the immune response and safet y 
profile b y age.
Perform a clinical as sessment including medical history ; record an y findings on the 
medical history  CRF.
Measure and record the participant’s temperature as appropriate for the age of the child, 
according to routine local practice (°F/ °C).
Confirm 
receipt of [ADDRESS_1010621] recent ( third or fourth) dose of 13vPnC for Cohorts 1and [ADDRESS_1010622] recent dose of 7vPnC or 13vPnC for 
Cohorts 3 and 4, if available.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 57Perform urine pregnancy test for female participants of childbearing potential 
(seeSection 8.2.4 ).
Forparticipants of child bearing potential, instruct the participant to use appropriate 
contraceptives until [ADDRESS_1010623] and document 
the conversation and the participant’s affirmation in the participant’s source document.
Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met and that none of the temporary  delay  criteria are met.
Assign an investigational product container number via the IRT.  This must be the last 
step before proceeding.  A sit e staff member will prepare the investigational product 
according to the IP manual.
After investigational product container number assignment :
Collect a blood sample of approximately  5mL for Cohort s 1 and 2, and approximately  
10mL for Cohort s 3 and 4, for immunogenicity  assessments prior to vaccination.
Administer a single 0.5 -mL injection of 20vPnC into the left leg (option for Cohort 1 
only) or left arm.
Permitted routine pediatric vaccines may  be given at the same time as study  vaccination 
according to local or national recommendations (to be administered into a limb other than 
the site of 20vPnC). However, if feasible, it isrecommended that licensed nonstudy  
vaccines be administered at least 14 day sor 28 day s (see Section 6.5.2) before or after 
20vPnC administration. The location of the injection of each vaccine administered at 
Visit 1 
(20vPnC and other , if applicable ) will be recorded on the CRF.
After vaccination:
Site staff will observe the participant for [ADDRESS_1010624] concomitant 
medications used to treat SAEs and NDCMCs.
Issue the participant’s parent(s)/legal guardian(s) a measuring device (caliper) 
to measure 
injection site reactions in the participant’s limb that received the 20vPnC and a digital 
thermometer to measure temperature , and provide instructions on their use.
Issue the participant’s parent(s)/legal guardian(s) an e- diary  (device or application).  
Provide instructions on use and completion of the e- diary .  Ask the participant’s 
parent(s)/legal guardian(s) to complete the e- diary from Day 1 to Day  7, with Day 1 
being the day  of vaccination.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 58Ask the participant’s parent(s)/legal guardian(s) to contact [CONTACT_407408] 7 -day postvaccination period if the participant 
has a fever >40.0 °C (>104.0 °F), redness an d/or swelling at the injection site (left leg 
[option for Cohort 1 only ]or left arm) measuring >14 measuring device units (>7 cm), or 
severe injection site pain (causes limitation of limb movement) to determine if the event 
requires further assessment by  [CONTACT_093].
Ask the participant or the participant’s parent(s)/legal guardian(s) to contact [CONTACT_739607] (eg, emergency  room visit or hospi[INVESTIGATOR_059]) occu
rs.
Provide the parent(s)/legal guardian(s) with the participant contact [CONTACT_634685] (see Section 10.1.10 ).
Inform the participant’s parent(s)/legal guardian(s) that the use of proph ylactic 
antipy retic/pain medication, while permitted, is not recommended on the day  of 20vPnC 
administration (before or after vaccination).
Record AEs, SAEs, and NDCMCs during the visit as described in Section 8.[ADDRESS_1010625] 
concomitant medications as described in Section 6.5.3.
The investigator or an authorized designee completes the CRF and updates the 
investigational product accountability  records.
The investigator or appropriately  qualified designee reviews the e -diary  data online at 
frequent intervals for the 7 day s following vaccination to evaluate participant compliance 
and as part of the ongoing safet y review.
8.10.2. Visit 2 (Follow -up: 28 to 42 Days After Visit 
1, ie, Study Day 29 to 43)
Record nonstud y vaccinations administered since Visit 1, as described in Section 6.5.3.
Perform a contraception check (see Section 10.4), if applicable ( Cohort 3 and Cohort 4 
only).
Ensure and document that the participant continues to be eligible for the study  
(seeSection 7.2 for participant discontinuation/withdrawal) and that the temporary  delay  
criteria for the immunogen icity blood draw 
arenot met.
Review the participant’s e -diary data with the participant’s parent(s)/legal guardian(s); 
collect stop dates of an y e-diary  events ongoing on the last day  that the e -diary  was 
completed and record stop dates in the CRF.
Collect the e- diary  (if applicable ).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 59Determine whether an y AEs (includes nonserious AEs, SAEs, and NDCMCs) have 
occurred since the previous visit and follow up on any  previousl y reported events to 
determine the outcome (ie, record stop dates or confirm if they  are still continuing) and 
record as described in Section 10.[ADDRESS_1010626] concomitant medications used to treat 
NDCMCs and SAEs.
Collect a blood sample of approximately  5mL for Cohort s 1 and 2, and approximately  
10mL for Cohort s 3 and 4, for immunogenicity  (a topi[INVESTIGATOR_634666]).
Remind the participant or the participant’s parent(s)/legal guardian(s) to contact [CONTACT_739608] (eg, emergency  room visit or hospi[INVESTIGATOR_059]) occurs.
Confirm whether the parent(s)/legal guardian(s) still possesses the participation contact 
[CONTACT_1137].
The investigator or an authorized designee completes the CRF and the source documents.
8.10.3. Visit 3 (6- Month Safety Collection [Telephone Contact] –168 to 196 Days After 
Visit 1)
Contact [CONTACT_2299]’s parent(s)/legal guardian(s) by  [CONTACT_85790]  
6months after the stud y vaccination; this contact [CONTACT_739609], unless the participant’s parent(s)/legal gua rdian(s) 
has withdrawn consent.
Determine whether an y SAEs and NDCMCs have occurred since the previous visit and 
follow up on an y previo usly reported events to determine the outcome (ie, record stop 
dates or confirm if they  are still continuing) and record as described in Section 10.[ADDRESS_1010627] concomitant medications used to treat NDCMCs and SAEs.
The investigator or an authorized designee completes the CRF and the source documents.
8.10.4. Unscheduled Visits
If the participant’s parent(s)/legal guardian(s) reports redness or swelling at the injection site 
(left leg [option for 
Cohort 1 only ]or left arm) measuring >14 measuring device units 
(>7 cm) or severe injection site pain or a fever >40.0°C (>104.0°F) d uring the 7- day 
postvaccination period, a telephone contact [CONTACT_739610] y qualified designee and participant’s parent(s)/legal guardian(s) to 
assess if an unscheduled investigator site visit is require d.  Note that for a fever 
>40.0°C (>104.0°F), the participant’s parent(s)/legal guardian(s) should be instructed not to 
delay  seeking medical care, as appropriate, while arranging for an unscheduled visit if 
needed .  An investigator site visit should be sc heduled as soon as possible to assess the extent 
of the injection site reaction, unless any  of the following is true:

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 60The participant’s parent(s)/legal guardian(s) is unable to bring the participant to the 
unscheduled visit.
The reaction is no longer prese nt at the time of the telephone contact.
The participant’s parent(s)/legal guardian(s) recorded an incorrect value in the e -diary  
(confirmation of an e -diary  data entry  error).
The principal investigator (PI) or authorized designee determined it was not ne eded.
This telephone contact [CONTACT_214356]’s source documentation and the 
CRF.
If the participant’s parent(s)/legal guardian(s) is unable to bring the participant to an 
unscheduled visit, or the PI  [INVESTIGATOR_214313], an y 
ongoing reactions must be assessed at the next study  visit.
During the investigator site visit, the reactions should be assessed b y the investigator or a 
medically  qualified member of the study  staff such as a study  physician or a stud y nurse, as 
applicable to the investigator’s local practice, who will:
Measure temperature as appropriate for the age of the child, according to routine local 
practice ( °F/°C).
Measure minimum and maximum diameters of redness (if present).
Measure minimum and maximum diameters of swelling (if present).
Assess injection site pain in accordance with the grades provided in Section 8.2.2
(ifpresent).
Assess for other findings associated with the reaction and record on the AE page of the 
CRF, if appropriate.
The investigator or an authorized designee will complete the unsch eduled visit assessment 
page of the CRF.
The participant’s parent(s)/legal guardian(s) will also be instructed to contact [CONTACT_634687] y em ergency room visit or hospi[INVESTIGATOR_407374], drowsiness/ increased sleep, and/or irritability in Cohort 1, or fatigue, headache, 
muscle pain, and/or joint pain in 
Cohorts 2 through 4, or for a local reaction (all groups) in 
the7 day s following vaccination.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010628] 2021
PFIZER CONFIDENTIAL
Page 61The participant’s parent(s)/legal guardian(s) will also be instructed to contact [CONTACT_739611], medical event, or hospi[INVESTIGATOR_221256].  The investigator site should determine if an unscheduled visit to further evaluate the event is warranted in all such cases.
Additionally, study staff may contact [CONTACT_2299]’s parent(s)/legal guardian(s) to obtain 
additional information on Grade 3 events entered into the e-diary.
9. STATISTICAL CONSIDERATIONS
Methodology for summary and statistical analyses of the data collected in this study is 
described here and further detailed in a statistical analysis plan (SAP), which will be maintained by [CONTACT_456].  The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Estimands and Statistical Hypotheses
9.1.1. EstimandsThe estimands corresponding to each primary, secondary  objective are
described in the table in Section 3 .
The estimands for evaluating the immunogenicity objectives are based on the evaluable 
population (see Section 9.3 for definition) and estimate the vaccine effect in the hypothetical 
setting where participants follow the study schedule and protocol requirements. The estimand addresses the objective of estimating the true difference in the immune response between the 2 time points within each cohort, since noncompliance may obscure the truedifference in immune response between the 2 time points in each cohort.  Missing serology results will not be imputed. Immunogenicity results that are below the LLOQ will be set to 0.5 × LLOQ in the analysis.
In the safety evaluation, missing e-diary data will not be imputed.  A missing AE start date
will be imputed according to [COMPANY_007] standard rules following a conservative principle to characterize the AE in the safety analysis, with details further described in the study SAP. No other missing information will be imputed in the safety analysis.CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 629.1.2. Statistical Hypotheses
[IP_ADDRESS]. Cohort 1 andCohort 2
For theprimary  immunogenicity  objective, hypothesis testing will be used to assess 
superiority  of the IgGconcentration sforthe 7 additional pneumococcal seroty pes1month 
after 20vPnC to the IgGconcentration s before 20vPnC within each cohort .  The null 
hypothesis (H 0) for a seroty pe is
H0:
µfold-rise≤1.0
where
µfold-riseis the geometric mean of the fold riseinIgG concentration from before to 
1month after vaccination ;
The null hy pothesis (H0)will be rejected for a seroty pe ifthe lower bound of the 2- sided 
95% CI forthe IgGGMFRis greater than 1.0.
[IP_ADDRESS]. Cohort 3 and Cohort 4
For the primary  immunogenicity  objective , hypothesis testing will be used to assess 
superiority  of the OPA titers forthe 7 additional pneumococcal serot ypes 1 month after 
20vPnC to the OPA titers before 20vPnC within each cohort in a randomly  selected subset of 
participants.  The null hypothesis (H 0) for a serotype is
H0: µfold-rise≤1.0
where
µfold-riseis the geometric mean of the fold change in OPA titer from before to 1 month 
after vaccination ;
The null hy pothesis (H0)will be rejected for a seroty pe ifthe lower bound of the 2- sided 
95% CI forthe OPA GMFR is greater than 1.0.
9.1.3. Multiplicity Considerations
The primary  immunogenicity  objectives for superiority are evaluated separately  for each
cohort. Within each cohort, superiority  of the immune response 1 month after 20vPnC to 
before vaccination ( seroty pe-specific IgG
concentration s for Cohorts 1 and 2;
seroty pe-specific OPA titersfor Cohorts 3 and 4) isassessed b ythehypothesis test sas 
described in Section [IP_ADDRESS] or Section 
[IP_ADDRESS], each hy pothesis test at an alpha level of 0.05 
for each serot ype. The primary  immunogenicity  objectives will beachieved if the superiorit y 
oftheimmune response 1 month after 20vPnC to before 20vPnC is established for all 
7additional seroty pes in a give ncohort .  Therefore, the overall type Ierror ratefor 
immunogenicit y evaluatio nis well controlled atthe0.05 level for each cohort .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 639.2.Sample Size Determination
The study size is based on considerations of 1) the evaluations of safet y, tolerability, and 
immun ogenicit y of a single dose of 20vPnC in the population in each cohort , 2) operational 
constraints of available serum volumes from individual study  participants, and 
3)contribution to theoverall safet y datab ase for the 20vPnC pediatric clinical development 
program .
Safety Endpoints
The primary  safet y objective includes the endpoint of reported AEs within 1 month after 
vaccination. The number of participants receiving 20vPnC is 200 in each of Cohort s 1 
through 4. There is a greater than 90% chance of observing at least [ADDRESS_1010629] 2% ( Table 5).
Table 5. Probability of Detecting at Least 1 AE in E ach of Cohort s 1 Through 4
Sample Size True Rate of AEs Probability (%) of Observing at Least 1 AE
200 per Cohort 0.1% 18
200 per Cohort 0.5% 63
200 per Cohort 1% 87
200 per Cohort 2% 98
Immunogenicity Endpoints
Table 6 provides information on the probability  of demonstrating superiority  of IgG 
concentrations (Cohorts 1 and 2) and OPA titers (Cohorts 3 and 4) 1 month after 20vPnC 
compared with before 20vPnC based on data from the B7471003 Phase 2 20vPnC study  in 
infants and the B7471007 Phase 3 20vPnC study  in adults, respectivel y.
For IgG concentrations with 180 evaluable participants in each cohort (Cohort 1 or 
Cohort 2), there is a > 99% probability  that superiority  will be declared for all [ADDRESS_1010630] 50% 
of the observed GMFR sfrom before to 1 month after Dose 4 in the B7471003 study .  For 
OPA titers with 90 evaluable participants in each cohort (Cohort 3 or Cohort 4) , the 
probability  that superiority  will be declared for the 7 additional seroty pes ranges from 
64% (11A) to ≥99% 
(all other serot ypes except 33F) if the true GMFRs from before 20vPnC 
to 1month after 20vPnC are 75% of the observed GMFRs from before 20vPnC to 1 month 
after 20vPnC from part icipants 18 through 29 yearsof age in the B747100 7study .  If the 
assumed evaluable participants are increased to 180 and GMFR assumptions are unchanged,
the probability  to demonstrate superiorit y for 11A increase s to 91%.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010631] 2021
PFIZER CONFIDENTIAL
Page 64Table 6. Probability (%) to Demonstrate Superiority of Immune Response of 
1 Month After 20vPnC to Before 20vPnC
Serotype IgGa
(Cohorts 1 and 2)OPAb
(Cohorts 3 and 4)
Assumption 1 Assumption 2 Assumption 3
8 >99 >99 >99 >99
10A >99 >99 >99 >99
11A >99 64 95 91
12F >99 >99 >99 >99
15B >99 >99 >99 >99
22F >99 >99 >99 >99
33F >99 98 >99 >99
Overall >99 63 95 91
Abbreviations: GMFR = geometric mean fold rise; IgG = immunoglobulin G; OPA = opsonophagocytic 
activity.
Note: The probability calculation assumes the variabilities for IgG concentration and OPA titers are the same 
as observed in infant study B7471003 and adult study B7471007 (18 through 29 years of age), respectively, 
using the t-distribution. Additional assumptions in the calculation:
a. The true IgG GMFR from before to 1 month after 20vPnC for each serotype to be 50% of the observed 
IgG GMFR from before to 1 month after Dose 4 of 20vPnC in Study 7471003, 180 evaluable participants 
in each cohort.
b. For Assumption 1, 2, or 3, respectively, the true OPA GMFR from before to 1 month after 20vPnC for 
each serotype to be 75%, 100%, or 75% of the observed OPA GMFR from before to 1 month after 
20vPnC from participants 18 through 29 years of age in Study B7471007, and 90, 90, or 180 evaluable 
participants in each cohort.
9.3. Populations for Analysis
For purposes of analysis, the following populations are defined:
Population Description
Enrolled All participants who have a signed ICD.
Evaluable immunogenicity All eligible participants who receive [ADDRESS_1010632] safety data reported after vaccination.CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010633] 2021
PFIZER CONFIDENTIAL
Page 659.4. Statistical Analyses
The SAP will be developed and finalized before database lock for any of the planned analysis 
in Section 9.5 and will describe the participant populations to be included in the analyses, 
and procedures for accounting for missing, unused, and spurious data.  This section is a summary of the planned statistical analyses of the primary, secondaryendpoints.
Immunogenicity and safety results will be analyzed separately for each cohort.9.4.1. Immunogenicity Analyses
The statistical analysis of pneumococcal immunogenicity results will be primarily based on 
the evaluable immunogenicity population as defined in Section 9.3 .
 
Participants will be summarized according to the vaccine group as randomized.
Missing serology data will not be imputed.
Endpoint Statistical Analysis Methods
Primary •Pneumococcal serotype-specific IgG GMFRs from before to 
1 month after 20vPnC
For each of the 20 serotypes in each cohort, GMFRs and the associated 
95% CIs for serotype-specific IgG concentrations from before to 1 month after vaccination will be provided. The GMFR will be calculated by [CONTACT_739612] (1 month after vaccination –before vaccination for each particip ant).  Two-sided CIs will be 
obtained by [CONTACT_739613]’s t-distribution for the mean difference of measures on the logarithmically transformed assay results and exponentiating the limits.
In Cohort 1 and Cohort 2, for each of the 7 additional serotypes, the 
lower limit of the 2-sided 95% CI of the IgG GMFR for a serotype will be used in the hypothesis test for superiority of IgG concentrations1 month after 20vPnC to before 20vPnC for that serotype, as detailed in Section [IP_ADDRESS] .CCICCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 66Endpoint Statistical Analysis Methods
Pneumococcal serotype -specific OPA GMFRs fr om before to 
1month after 20vPnC
For each of the [ADDRESS_1010634]  as the IgG GMFRs.
In Cohort 3 and Cohort 4, f or each of the 7 additiona l serot ypes, the 
lower limit of the 2-sided 95% CIof the OPA GMFR for a serot ype will 
be used in the h ypothesis t est for superiorit y of OPA titers 1 month after 
20vPnC to before 20vPnC for that serot ype, as detailed in 
Section [IP_ADDRESS] .
Secondary Percentages of participants with predefined pneumococcal 
serotype -specific IgG concentrations for the 7 additional serotypes 
at 1 month after 20vP nC
Percentages ( and 2 -sided 95% C Is) of participants with seroty pe-specific
IgG concentrations ≥ the predefined level will be provided for each of 
the 7 additional serot ypesin Cohort 1 .The Clopper -Pearson method 
will be used to calculate the CI s.
Percentages of participants with ≥4-fold rise inpredefined 
pneumococcal serotype- specific OPA titer sfor the 7 additional 
serotypes from before to 1 month after 20vPnC
Percentages ( and 2-sided 95% CIs)of participants with ≥4-fold rise in 
seroty pe-specific OPA titers from before to 1 month after 20vPnC will 
be provided for each of the 7 additional serot ypes in Cohorts 2, 3, and 4 . 
The Clopper -Pearson method will be used to calculate the CI s.
Pneumococcal serotype -specific IgG GMCs before and 1 month
after 20vPnC
GMCs and 2- sided 95% CI s for serot ype-specific IgG concentrations 
before and 1 month after vaccination will be provided for each serot ype 
in each age cohort . Geometric means and the associated 2 -sided CIs 
will be obtained by  [CONTACT_739614] t -distribution and then exponentiating the results.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010635] 2021
PFIZER CONFIDENTIAL
Page 67Endpoint Statistical Analysis Methods
•Pneumococcal serotype-specific OPA GMTs
OPA GMTs before and [ADDRESS_1010636] as IgG GMCs.
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
C
CI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010637] rules following a conservative principle to characterize the AE in the safety 
analysis, with details further described in the study SAP. No other missing information will be imputed in the safety analysis.
Endpoint Statistical Analysis Methods
Primary •Descriptive statistics will be provided for each reactogenicity endpoint 
for each age cohort. Local reactions and systemic events from Day 1 after vaccination through Day 7 will be presented by [CONTACT_407416]. Descriptive summary statistics will include counts and percentages of participants with the indicated endpoint and the associated 2-sided Clopper-Pearson 95% CIs.
•AEs will be categorized according to Medical Dictionary for Regulatory 
Activities (MedDRA) terms. Descriptive summary statistics (counts and percentages and the associated 2-sided Clopper-Pearson 95% CIs) for AEs from vaccination to 1 month after vaccination will be provided for each age cohort.
•SAEs and NDCMCs will be categorized according to MedDRA terms.  
Descriptive summary statistics (counts, percentages, and the associated 2-sided Clopper-Pearson 95% CIs) for SAEs and NDCMCs from C
CI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010638] 2021
PFIZER CONFIDENTIAL
Page 69Endpoint Statistical Analysis Methods
vaccination to 6 months after vaccination will be provided for each age 
cohort.
Secondary Not applicable.
9.5. Interim Analyses
There is no interim analysis planned for the study.
9.5.1. Analysis Timing
Safety data through the visit occurring 1 month after the dose from all participants may be 
analyzed by [CONTACT_407418]. All results will be analyzed and reported after the completion of the study.
 
 
 CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 7010. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight C onsiderations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines;
Applicable International Council for Harmonisation (I CH) GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protoco l amendments, I CD, IB, and other relevant documents 
(eg,advertisements) must be reviewed and approved by  [CONTACT_107095]/EC by  [CONTACT_107096]/EC before the study  is 
initiated.
Any amendments to th e protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing writte n summaries of the status of the study  to the IRB/EC annually  or more 
frequentl y in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/EC;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by [CONTACT_1744]/EC 
procedures;
Providing oversight of the conduct of the stud y at the site and adherence to requirements 
of 21 Code of Federal Regulations (CFR), ICH guidelines, the I RB/EC, European 
regulation 536/2014 for clinical studies (if applicable), and all other ap plicable local 
regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the inve stigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 71In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.
10.1.2. Financial Disclosure
Investigators and subinvestigators wi ll provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities.  I nvestigators 
are responsi ble for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant’s parent(s)/legal guardian(s) and answer all questions regarding the study .
The participant’s parent(s)/legal guardian(s) must be informed that their participation is 
voluntary .  The participant’s parent(s)/legal guardian(s) will be required to sign a statem ent 
of informed consent that meets the requirements of [ADDRESS_1010639] (HI PAA) requirements, 
where applicable, and the I RB/EC or study  center.
The investigator must ensure that each study  participant’s parent(s)/legal guardian(s) is full y 
informed about the nature and objectives of the study , the sharing of data related to the study , 
and possible risks associated with participation, including the risks associated with the 
processing of the participant’s personal data.
The participant’s parent(s)/legal guardian(s) must be informed that the participant’s personal 
study -related data will be used by  [CONTACT_10999].  
The level of disclosure must also be explained to the participant’s parent(s)/legal guardian(s).
The participant’s parent(s)/legal guardian(s) must be informed that the participant’s medical 
records may  be examined by  [CONTACT_17080] y Assurance auditors or other authorized 
personnel appointed b y the sponsor, b y appropriate I RB/EC members, and by  [CONTACT_78273].
The investigator further must ensure that each study  participant’s parent(s)/legal guardian(s) 
is fully  informed about his or her right to acc ess and correct the participant’s personal data 
and to withdraw consent for the processing of the participant’s personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was obtained.  
The authorized person obtaining the informed consent must also sign the ICD.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 72The participant’s parent(s)/legal guardian(s) must be reconsented to the most current version 
of the I CD(s) during the parti cipant’s participation in the study .
A cop y of the ICD(s) must be provided to the participant’s parent(s)/legal guardian(s).
If a participant reaches the age at which he or she is legall y able to provide consent 
(eg,18 years old) during the study, his or her consent must be obtained. Since the participant 
is no longer a minor, the consent of the 
parent(s)/legal guardian(s) is no longer valid. Once 
the participant provides consent, the participant then becomes responsible to directly  
participate in stud y procedures and assessments. This is expected for a minority  of 
participants in the study , and therefore any  references in the protocol to parent(s)/legal 
guardian(s) may , in certain cases, be directl y applicable to the participant.
10.1.4. Data Protection
All par ties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic a nd/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be rec overed in the event of 
disaster.  In the event of a potential personal data breach, the study  site shall be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  [CONTACT_2371].
To pr otect the rights and freedoms of natural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code.  
Any participant records or data sets that are transferred to the sponsor will con tain the 
numerical code; participant names will not be transferred.  All other identifiable data 
transferred to the sponsor will be identified by  [CONTACT_20007], participant -specific code.  The 
study  site will maintain a confidential list of participants who participated in the study , 
linking each participant’s numerical code to his or her actual identity .  In case of data 
transfer, the sponsor will protect the confidentiality of participants’ personal data consistent 
with the clinical study  agreement and appl icable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on 
www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Databas e (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.  I n addition, [COMPANY_007] reports study  results outside of the 
requirements of local laws/regulations pursuant to its standard operating proced ures (SOPs).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 73In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted.  The seresults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial results on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009] .
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (clinical study  report [C SR]synopses in which any  
data that could be used to identify  individual participants have been remov ed) on 
www.pfizer.com for [COMPANY_007]- sponsored interventional studies at the same time the 
corresponding stud y results are posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the European Medicines Agency  (EMA) website.  Clinical data, under Phase 1 of this 
policy , includes clinical overviews, clinical summaries, CSRs, and appendices containing the 
protocol and protocol amendments, sample CRFs, and statistical methods.  Clinical data, 
under Phase 2 of this policy , includes the publishing of individual participant data.  Policy  
0070 applies to new marketing authorization applications submitted via the centralized 
procedure since 01 January 2015 and applications for line extensions and for new indications 
submitted via the centralized procedure since 01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “b ona-fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class.  [COMPANY_007] will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordan ce with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 74Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.  Research teams must include a biostatistician.  Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the st udy will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data).  The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -
related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.  This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk
-based initiatives in operations and quality  
such as risk management and mitigation strategies and anal ytical risk- based monitoring), 
methods, responsibilities, and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring), are provided in the
monitoring plan.
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protecte d; and that the study is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 years after study  completion unless local regulations or 
institutional policies require a longer retention period.  No records may  be destroy ed during 
the retention period without the written approval of t he sponsor.  No records may  be 
transferred to another location or part y without written notification to the sponsor.  The 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 75investigator must ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator s ite and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copi[INVESTIGATOR_19946].  Before re sponse 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.  Source documents are filed at the investigator site.
Data reported on the CRF or entered in the electronic CRF (eCRF) that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be 
explained.  The investigator may
 need to request previous medical records or transfer 
records, depending on the study .  Also, current medical records must be available.
Definition of what constitutes source data can be found in the ISF.
10.1.8. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor.  Study  sites will be closed upon 
study  completion .  A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the contract 
resear ch organization (CRO) if requested to do so by  [CONTACT_22846]/EC or if such 
termination is required to protect the health of study participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure o f the investigator to comply  with the protocol, the requirements of the I RB/EC 
or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_093];

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 76Discontinuation of further study  interventi on development.
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 18 months after end of the stud y 
(or study  termination), whichever comes first.
The investigator agrees to refer to the primary  publicatio n in any  subsequent publications 
such as secondary  manuscripts and submits all manuscripts or abstracts to the sponsor 
30days before submission.  This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] 
intervention -related information necessary  for the appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the study , the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites.  I n accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
indivi dual site data.  I n this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal E ditors authorship 
requirements.
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_240872]
.
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, the participant’s parent(s)/legal guardian(s) are provided with a 
contact [CONTACT_1137].  The contact [CONTACT_4662], at a minimum, protocol and investigational product 
identifiers, participant numbers, contact [CONTACT_22850], and contact 
[CONTACT_4664] a contact [CONTACT_739615] 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 77provide advice on a medical question or problem originating from another healthcare 
professional not involved in the participant’s participation in the study .  The contact [CONTACT_107101] b y investigator staff if they are seeking advice on medical questions or 
problems; however, it should be used only in the event that the established communication 
pathway s between the investigator site and the study  team are not available.  I t is therefore 
intended to augment, but not replace, the established communication pathway s between the 
investigator site and the study  team for advice on medical questions or problems that may  
arise during the stud y.  The contact [CONTACT_8865] b y the participant’s 
parent(s)/legal guardian(s) directl y, and if the participant’s parent(s)/legal guardian(s) calls 
that number, he or she will be directed back to the investigator site.
10.2. Appendix 2: Clinical Laboratory Tests
Not a pplicable .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 7810.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
temporally  associated with the use of study  intervention, whether or not considered 
related to the stud y intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (eg, electrocardiogram [ECG ] , radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator (ie, not related to 
progression of underly ing disease).
Exacerbation of a chronic or intermittent pr eexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.  Overdose per se will not be reported as an 
AE/SAE unless i t is an intentional overdose taken with possible suicidal/self -harming 
intent.  Such overdoses should be reported regardless of sequelae.
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as an AE or SAE if they fulfill the definition of an AE or SAE. Also, “lack of 
efficacy ” or “failure of expected pharmacological action” constitutes an AE or SAE.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 79Events NOT Meeting the AE Definition
Events that, in the clinical judgment of the investigator, are 1) consistent with normal 
growth and development and 2) do not differ significantly  in frequency  or severit y 
from expected, are not generall y to be considered adverse events. Examples may  
include, but are not limited to, teething, contact [CONTACT_407422], spi[INVESTIGATOR_739591], colic, or 
typi[INVESTIGATOR_407372]/cry ing in infants and children.
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_739616] s evere than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads 
to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pree xisting disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of an NDCMC
An NDCMC is defined as a disease or medical condition, not previously  identified, that is 
expected to be persistent or is otherwise long -lasting in its effects.
10.3.3. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 80An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event.  I t does not refer to an event that 
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting.  Complications that occur during hosp italization are AEs.  If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life function s.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_739592].  These events should usually  be considered 
serious.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 81Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hosp italization, or development of drug dependency or 
drug abuse.
Suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic or 
non-pathogenic, is considered serious.  The event may  be suspected from clinical 
symptoms or laboratory  
findings indicating an infection in a patient exposed to a [COMPANY_007] 
product.  The terms “suspected transmission” and “transmission” are considered 
synony mous.  These cases are considered unexpected and handled as serious expedited 
cases b y pharmacovigilance personnel.  Such cases are also considered for reporting as 
product defects, if appropriate.
10.3.4. Recording/Reporting and Follow -up of AEs and/or SAEs
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF 
and for reporting SAE s on the Vaccine SAE Report ingForm to [COMPANY_007] Safety .  These 
requirements are delineated for 3 t ypes of events: (1) SAEs; (2) nonserious AEs; and 
(3)exposure to the investigational product under study  during pregnancy  or breastfeeding, 
and occupational exposure.
It should be noted that the Vaccine SAE Report ingForm for reporting of SAE information 
is not the same as the AE page of the CRF.  When the same data are collected, the forms 
must be completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the Vaccine SAE
Report ingForm for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the Vaccine 
SAE Report ingForm to 
[COMPANY_007] Safety Within 24 
Hours of Awareness
SAE All All
Nonserious AE All None

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 82Exposure to the 
investigational product 
under study  during 
pregnancy  or 
breastfeeding, and 
occupational exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Occupational exposure is 
not recorded.All (and EDP supplemental 
form for EDP)
Note:  I nclude all SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding . Include all 
AEs/SAEs associated with 
occupational exposure.
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to [COMPANY_007] Safety  in lieu of completion of the Vaccine SAE Report ing
Form/AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_404205] y.  In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_1093] m edical records before 
submission to [COMPANY_007] Safety .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis 
(notthe individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities.  An AE tha t is assessed as 
severe should not be confused with an SAE.  Severe is a category  utilized for rating the 
intensity  of an event; and both AEs and SAEs can be assessed as severe.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 83An event is defined as “serious” when it meets at least 1 of the predefined ou tcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
GRADE If required on the AE page of the CRF, the investigator will use the 
adjectives MILD, MODERATE, or SEVERE to describe the maximum 
intensity  of the AE. For purposes of consistency , these intensity  grades are 
defined as follows:
1 MILD Does not interfere with participant's usual 
function.
2 MODERATE Interferes to some extent with participant's usual 
function.
3 SEVERE Interferes significantl y with participant's usual 
function.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention and 
each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor.  However, it is very 
important that the investigator always make an assessment of causality for every 
event before the initial transmission of the SAE data to the sponsor.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 84The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know w hether or not the investigational product caused the 
event, then the event will be handled as “related to investigational product” for 
reporting purposes, as defined by  [CONTACT_456].  In addition, if the investigator 
determines that an SAE is associated wit h study  procedures, the investigator must 
record this causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the Vaccine SAE Report ingForm and in 
accordance with the SAE reporting requirements.
Follow-up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_215867]/or causalit y of the AE or SAE as f ully as possible.  This 
may include additional laboratory  tests or investigations, histopathological 
examinations, or consultation with other healthcare professionals.
If a participant dies during participation in the study or during a recognized follow -up
period, the investigator will provide [COMPANY_007] Safety  with a copy  of an y postmortem 
findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the spon sor within 24 hours of 
receipt of the information.
10.3.5. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) in order to report the event within 24 hours.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 85The site will enter the SAE data into the electronic system as soon as the data become 
available.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see next 
section) or to [COMPANY_007] Safety b y telephone.
SAE Reporting to [COMPANY_007] Safety via Vaccine SAE Report ingReport Form
Facsimile transmission of the Vaccine SAE Report ingForm is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification b y telephone is 
acceptable w ith a cop y of the Vaccine SAE Report ingForm sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Vaccine SAE Report ingForm pages within the designated 
report ing time frames.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010640] 2021
PFIZER CONFIDENTIAL
Page 86CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010641] 2021
PFIZER CONFIDENTIAL
Page 87CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010642] 2021
PFIZER CONFIDENTIAL
Page 88CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010643] 2021
PFIZER CONFIDENTIAL
Page 8910.5. Appendix 5: Genetics
Not applicable.CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 9010.6. Appendix 6: Liver Safety: Suggested Actions and Follow- up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transien t liver injury , but adapt 
are termed “adaptors.”  In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as drug -induced 
liver injury  (DILI).  Participants who experience a transaminase elevation above 3 times the 
upper limit of normal ( ×ULN) should be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
Liver function tests (LFTs) are not required as a routine safet y monitoring procedure in this 
study .  However, should an investigator deem it necessary  to assess LFTs because a 
participant presents with clinical signs/s ymptoms, such LFT results should be m anaged and 
followed as described below.
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  [CONTACT_74097].  The increase in TBi li typi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same laboratory  
sample).  In rare instances, by  [CONTACT_22858], AST/AL T values might 
have decreased.  Th is occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditi ons.  Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value >2 ×ULN 
with no evidence of hemoly sis and an alkaline phosphatase value <2 ×ULN or not 
available.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT values 
>2times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is smaller).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 91Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches >3 ×ULN 
(whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The parti cipant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_1010644] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time (PT)/internation al 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over -the-counter medi cations) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum sample for acetaminophen drug and/or protein adduct levels may  be warranted.
All case s demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’ s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
10.7. Appendix 7: ECG Findings of Potential Clinical Concern
Not applicable.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 9210.8. Appendix 8: Medical Device Adverse Events, Adverse Device Effects, Serious 
Adverse Events, and Devi ce Deficiencies: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Definitions of a Medical Device Incident
The definitions and procedures detailed in this appendix are in accordance with I SO [ZIP_CODE].
Both the investigator and the sponsor will comply  with all local medical device reporting 
requirements.
The detection and documentation procedures described in this protocol apply  to all sponsor 
medical devices provided for use in the stud y (see Section 6.1.[ADDRESS_1010645] of sponsor 
medical devices).
10.8.1. Definition of AE and ADE
AE and ADE Definition
An AE is defined as an y untoward medical occurrence, unintended disease or 
injury , or untoward clinical signs (including abnormal laboratory  finding) in study  
participants, users, or other persons, whether or not related to the investigational 
medical devi ce.  This definition includes events related to the investigational 
medical device or comparator for stud y participants, users, and other persons.  This 
definition also includes events considered related to  procedures for stud y 
participants only .
An ADE i s defined as an adverse event related to the use of an investigational 
medical device.  This definition includes any adverse events resulting from 
insufficient or inadequate instructions for use, deployment, implantation, 
installation, or operation, or an y malfunction of the investigational medical device 
as well as an y event resulting from use error or from intentional misuse of the 
investigational medical device.
10.8.2. Definition of SAE, SADE, and Unanticipated Serious Adverse Device Effect
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 93An SAE is an AE that:
a.Led to death.
b.Led to serious deterioration in the health of the participant, that either resulted in:
A life -threatening illness or injury .  The term “life -threatening” in the definition of 
serious refers to an event in which the participant was at risk of death at the time of 
the eve nt.  It does not refer to an event that hy pothetically  might have caused death, 
if it were more severe.
A permanent impairment of a bod y structure or a body function.
Inpatient or prolonged hospi[INVESTIGATOR_059].  Planned hospi[INVESTIGATOR_272] a preexisting 
condit ion, or a procedure required b y the protocol, without serious deterioration in 
health, is not considered an SAE.
Medical or surgical intervention to prevent life- threatening illness or injury  or 
permanent impairment to a body  structure or a body  function.
c.Led to fetal distress, fetal death, or a congenital abnormality  or birth defect.
SADE Definition
An SADE is defined as an adverse device effect that has resulted in an y of the 
consequences characteristic of a serious adverse event.
[LOCATION_003]DE Definition
A [LOCATION_003]DE is a serious adverse device effect which by [CONTACT_5942], incidence, 
severit y, or outcome has not been identified in the current version of the risk 
analysis management file.
10.8.3. Definition of Device Deficiency
Device Deficiency Definition
A device deficiency  is an inadequacy  of a medical device with respect to its 
identity , quality , durability , reliability , safet y, or performance.  Device deficiencies 
include malfunctions, use errors, and inadequate labeling.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 9410.8.4. Recording/Reporting and Follow -up of A Es and/or SAEs and Device 
Deficiencies
AE, SAE, and Device Deficiency Recording
When an AE/SAE/device deficiency  occurs, it is the responsibility  of the 
investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  
reports, and diagnostic reports) related to the event.
The investigator will then record all relevant AE/SAE/device deficiency  
information in the participant’s medical records, in accordance with the 
investigator’s normal clinical practice and on the appropriate form o f the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of following the reporting process described 
in the I P manual.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety.  In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE/SAE.
For device deficiencies, it is very  important that th e investigator describes any  
corrective or remedial actions taken to prevent recurrence of the incident.
A remedial action is an y action other than routine maintenance or servicing of a 
medical device where such action is necessary  to prevent recurrence of a device 
deficiency .  This includes any  amendment to the device design to prevent 
recurrence.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE/SAE/device deficiency  
reported during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort and no t interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 95Severe: An event that prevents normal every day activities.  An AE that is assessed 
as severe should not be confused with an SAE.  Severe is a category  utilized for 
rating the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE/device deficiency .
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE/SAE/device deficiency , the investigator must document in the 
medical notes that he/she has reviewed the AE/SAE/device deficiency  and has 
provided an assessment of causalit y.
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator alway s make an assessment of causality for 
every  event b efore the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is on e of the criteria used when determining regulatory  
reporting requirements.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 96Follow -up of AE/SAE/Device Deficiency
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE/SAE/device deficiency  as 
fully  as possible.  This may  include additional laboratory  tests or investigations, 
histopathological examinations or consultation with other healthcare providers.
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.8.5. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 2 4 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a pape r SAE form 
(seenext section) or to [COMPANY_007] Safet y by [CONTACT_756].

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 97SAE Reporting to [COMPANY_007] Safety via Vaccine SAE Reporting Form
Facsimile transmission of the Vaccine SAE Reporting Form is the preferred 
method to transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification b y telephone is 
acceptable with a cop y of the Vaccine SAE Reporting Form sent by  [CONTACT_407423].
Initial notification via telephone does not replace the need for the inves tigator to 
complete and sign the Vaccine SAE Reporting Form pages within the designated 
reporting time frames.
10.8.6. Reporting of SADEs
SADE Reporting to [COMPANY_007] Safety
NOTE: There are additional reporting obligations for medical device incidents that are 
potentially  related to SAEs that must fulfill the legal responsibility to notify  appropriate 
regulatory  authorities and other entities about certain safet y information relating to medical 
devices being used in clinical studies.
Any device deficiency  that is associated with an SAE must be reported to the 
sponsor within 24 hours after the investigator determines that the event meets the 
definition of a device deficiency .
The sponsor shall review all device deficiencies and determine and document in 
writing wh ether they  could have led to an SAE.  These shall be reported to the 
regulatory  authorities and I RBs/ECs as required by  [CONTACT_2091].
10.9. Appendix 9: Country -Specific Requirements
Not applicable .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010646] 2021
PFIZER CONFIDENTIAL
Page 9810.10. Appendix 10: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
7vPnC 7-valent pneumococcal conjugate vaccine
13vPnC 13-valent pneumococcal conjugate vaccine
20vPnC 20-valent pneumococcal conjugate vaccine
ACIP Advisory Committee on Immunization Practices
ADE adverse device effect
AE adverse event
ALT alanine aminotransferase
AOM acute otitis media
AST aspartate aminotransferase
CAP communit y-acquired pneumonia
CBER Center for Biologics Evaluation and Research
CDC Centers for Disease Control and Prevention
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CRM [ADDRESS_1010647] European Clinical Trials Database
FDA Food and Drug Administration
GCP Good Clinical Practice
GGT gamma-glutamyl transferaseCCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014Final Protocol Amendment 1, [ADDRESS_1010648]
HIV human immunodeficiency virus
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IgG immunoglobulin G
IND investigational new drug 
INR international normalized ratio
IP manual investigational product manual
IPD invasive pneumococcal disease
IRB institutional review board
IRT interactive response technology
ISF investigator site file
ISO International Organization for Standardization
IUD intrauterine device
IUS intrauterine hormone-releasing system
IWR interactive Web- based response
LFT liver function test
LLOQ lower limit of quantitation
MedDRA Medical Dictionary for Regulatory Activities
N/A not applicable
NDCMC newly diagnosed chronic medical condition
OPA opsonophagocytic activity
PCD primary completion date
PI [INVESTIGATOR_739593]23 23-valent pneumococcal polysaccharide vaccine
PT prothrombin time
SADE serious adverse device effect
SAE serious adverse event
SAP statistical analysis plan
SoA schedule of activities
SOP standard operating procedure
SRM study reference manual
SRSD single reference safety document
S[LOCATION_003]R suspected unexpected serious adverse reactionCCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 100Abbreviation Term
TBili total bilirubin
ULN upper limit of normal
US [LOCATION_002]
[LOCATION_003]DE unanticipated serious adverse device effect
VT vaccine -type
WHO World Health Organization
WOCBP woman of childbearing potential

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].REFERENCES
1Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal 
pneumonia among adults: a sy stematic review and meta -analysis of diagnostic 
techniques. PL oS One 2013;8(4):e60273.
2O'Brien KL, Wolfson L J, Watt JP, et al. Burden of disease caused by  
[CONTACT_739617] 5 years: global estimates. Lancet
2009;374(9693):893- 902.
3Huang SS, Johnson KM, Ray  GT, et al. Healthcare utilization and cost of 
pneumococcal disease in the [LOCATION_002]. Vaccine 2011;29(18):3398 -412.
4Iyer AS, Ohtola JA, Westerink MAJ. Age -related immune response to pneumococcal 
polysaccharide vaccination: lessons for the clinic. Expert Rev Vaccines 2015;14(1):85 -
97.
5Wahl B, O’Brien KL, Greenbaum A, et al. Global burden of Streptococcus pneumoniae
in children younger than 5 years in the pneumococcal conjugate vaccines (PCV) era: 
2000- 2015. 10th I nternational Sy mposium on Pneumococci & Pneumococcal Diseases 
(IS[COMPANY_003] -10); 26
-30 Jun 2016; Glasgow, Scotland.
6Moore MR, L ink-Gelles R, Schaffner W, et al. Effect of us e of 13 -valent 
pneumococcal conjugate vaccine in children on invasive pneumococcal disease in 
children and adults in the [LOCATION_003]: analy sis of multisite, population- based surveillance. 
Lancet Infect Dis 2015;15(3):301-9.
7Ladhani SN, Collins S, Djennad A, et a l. Rapid increase in non- vaccine seroty pes 
causing invasive pneumococcal disease in England and Wales, 2000 –17: a prospective 
national observational cohort study . Lancet Infect Dis 2018;18:441 -
51.
8European Centre for Disease Prevention and Control. I nvasive pneumococcal disease. 
In: ECDC. Annual epi[INVESTIGATOR_93282] 2017. Stockholm: ECDC ; 2018. 
Available from : 
https://www.ecdc.europa.eu/sites/portal/files/documents/AER_for_2017 -invasive -
pneumo
coccal -disease.pdf . Accessed :[ADDRESS_1010649] Dis 
2015;61(5):767 -75.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 10210Stockmann C, Ampofo K, By [CONTACT_407425] , et al. Pneumococcal meningitis in children:  
epi[INVESTIGATOR_623] , seroty pes, and outcomes from 1997 -2010 in Utah. Pediatrics 
2013;132(3):[ADDRESS_1010650], et al. Invasive pneumococcal disease in children’s 
hospi[INVESTIGATOR_600]: 2014–2017. Pediatrics 2019;144(3):e20190567.
12JainS, Williams DJ, Arnold SR, et al. Community -
acquired pneumonia requiring 
hospi[INVESTIGATOR_287691] U.S. children. N Engl J Med 2015;372(9):835-45.
13JainS, Self WH, Wunderink RG, et al. Community- acquired pneumonia requiring 
hospi[INVESTIGATOR_739594] U.S. adults. N Engl J Med 2015;373(5):415 -27.
14Griffin MR, Zhu Y, Moore MR, et al. U.S. hospi[INVESTIGATOR_407379] a 
decade of pneumococcal vaccination. N Engl J Med 2013;369(2):155 -63.
15Marom T, Tan A, Wilkinson GS, et al. Trends in otitis media –related health care use in 
the [LOCATION_002], 2001 -2011. JAMA Pediatr 2014;168(1):68 -
75.
16Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their t ypes: past, 
present, and future. Clin Microbiol Rev 2015;28(3):871 -99.
17Hausdorff WP, Hanage WP. I nterim results of an ecological experiment— conjugate 
vaccination against the pneumococcus and serot ype replacement. Hum Vaccin 
Immunother 2016;12(2):358 - 74.
18AlonsoDeVelasco E, Verheul AFM, Verhoef J, et al. Streptococcus pneumoniae : 
virulence factors, pathogenesis, and vaccines. Microbiol Rev 1995;59(4):591 -603.
19Centers for Disease Control and Prevention. Prevention of pneumococcal disease: 
recommendations of the Advisory  Committee on Immunization Practices (ACI P). 
MMWR Recomm Rep1997;46(RR -8):1
-24.
20Austrian R. A brief history  of pneumococcal vaccines. Drugs Aging
1999;15(Suppl 1):1-10.  
21Shapi[INVESTIGATOR_5539], Berg AT, Austrian R, et al. The protective efficacy  of poly valent 
pneumococcal poly saccharide vaccine. N Engl J Med 1991;325( 21):1453-60.
22Stein KE. Thy mus- independent and thy mus- dependent responses to pol ysaccharide 
antigens. J I nfect Dis 1992;[ADDRESS_1010651] 1:S49 -S52.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 10323Borrow R, Health PT, Siegrist CA. Use of pneumococcal poly saccharide vaccine in 
children: what is the evidence? Curr Opin Infect Dis 2012;25(3):292 -303.
24Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal pol ysaccharide 
vaccine in older adults. N Engl J Med 2003;348(18):[ADDRESS_1010652] invasive disease and hospi[INVESTIGATOR_307] -treated 
pneumonia among people aged ≥65 years: a retrospective case -control study . Clin 
Infect Dis 
2015;60(10):1472-80.
26Wright PF, Sell SH, Vaughn WK, et al. Clinical studies of pneumococcal vaccines in 
infants. II. Efficacy  and effect on nasophary ngeal carriage. Rev Infect Dis 1981;[ADDRESS_1010653]:S108 -S112.
27Torres A, Bonanni P, Hryniewicz W, et al. Pneumococcal vaccination: what h ave we 
learnt so far and what can we expect in the future? Eur J Clin Microbiol Infect Dis
2015;34(1):19 -
31.
28Robinson KA, Baughman W, Rothrock G, et al. Epi[INVESTIGATOR_407380], 1995 -1998: opportunities for 
prevention in the conjugate vaccine era. JAMA 2001;285(13):[ADDRESS_1010654] invasive disease: implications for conjugate vaccine formulation and use, part I. 
Clin Infect Dis 2000;30(1):100 -21.
30Hausdorff WP, Bry ant J, Kloek C, et al. The contribution of specific pneumococcal 
serogroups to different disease manifestations: implications for conjugate vaccine 
formulation and use, part II. Clin I nfect Dis 2000;30(1):1 22-40.
31Nuorti JP, Whitney  CG. Prevention of pneumococcal disease among infants and 
children 
-use of 13-valent pneumococcal conjugate vaccine and 23- valent 
pneumococcal poly saccharide vaccine -recommendations of the Advisory  Committee 
on Immunization Pr actices (ACI P). MMWR Recomm Rep 2010;59(RR -11):1-18.
32Johnson HL , Deloria -Knoll M, L evine OS, et al. Sy stematic evaluation of seroty pes 
causing invasive pneumococcal disease among children under five: the Pneumococcal 
Global Seroty pe Project. PLoS Med 2010;7(10):[ADDRESS_1010655] Dis
2013;19(7):1074 -
83.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 10434Black SB, Shinefield HR, L ing S, et al. Effectiveness of heptavalent pneumococcal 
conjugate vaccine in children younger than five years of age for prevention of 
pneumonia. 
Pediatr Infect Dis J 2002;21(9):810-5.
35Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal 
conjugate vaccine in children y ounger than 5 y ears of age for prevention of pneumonia: 
updated anal ysis using World Health Organization standardized interpretation of chest 
radiographs. Pediatr Infect Dis J 2006;25(9):[ADDRESS_1010656] pneumonia and invasive pneumococcal disease in The Gambia: 
randomised, double -blind, placebo -controlled trial. Lancet2005;365(9465):1139-46.
37Eskola J, Ki lpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine 
against acute otitis media. N Engl J Med 2001;344(6):403 -9.
38O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safet y of seven -valent conjugate 
pneumococcal vaccine in American Indian c hildren: group randomised trial. Lancet
2003;362(9381):355-61.
39Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal 
conjugate vaccine in children with and those without HIV infection. NEngl J Med 
2003;349(14):[ADDRESS_1010657] Dis 2010;201(1):32 -
41.
41Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13 -valent 
pneumococcal conjuga te vaccine received market authorization in Europe. Expert Rev 
Vaccines 2010;9(3):[ADDRESS_1010658] pneumococcal pneumonia in adults. N Engl J Med 2015;372(12):1114 - 25.
43Centers for Disease Control and Prevention. Licensure of a 13 -valent pneumococcal 
conjugate vaccine (PCV13) and recommendations for use among children --Advisory  
Committee on I mmunization Practices (ACIP), 2010.  MMWR Morb Mortal Wkly  Rep
2010;59(9):258 -61.
44Centers for Disease Control and Prevention. Licensure of 13 -valent pneumococcal 
conjugate vaccine for adults aged 50 years and older.  MMWR Morb Mortal Wkly  Rep
2012;61(21):394 -5.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 10545Prevenar [ADDRESS_1010659] characteristics. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Product_I nformation/human/001104/WC500057247.pdf. Accessed: 12 Sep 2016.
46European Medicines Agency. Prevenar 13 assessment report. 22 Jan 2015.  Available 
from: http://www.ema.europa.eu/docs/en_GB/document_ library /EPAR_ -
_Assessment_Report_ -_Variation/human/001104/WC500186805.pdf. Accessed: 
12 Sep 2016.
47World Health Organization. WHO prequalified vaccines. Pneumococcal (conjugate). 
Prevenar 13. Available from: 
https://extranet.who.int/gavi/PQ_Web/PreviewVac cine.aspx?nav=0&ID=221. Effective 
20 Aug 2010. Accessed: 12 Sep 2016.
48World Health Organization. WHO prequalified vaccines. Pneumococcal (conjugate). 
Prevenar 13 multidose vial. 
Available from: 
https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav =0&ID=317. 
Effective: 14 Jul 2016. Accessed: [ADDRESS_1010660] of 13 -valent pneumococcal 
conjugate vaccination in invasive pneumococcal disease incidence and mortality  
[erratum appears in Clin Infect Dis 2014;59(12):1812]. Clin I nfect Dis
2014;59(8):[ADDRESS_1010661] . Vaccine 2013;31(52) :6232 - 8.
51Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serot ypes in the 
13-valent pneumococcal conjugate vaccine. Vaccine 2011;29(49):9127 - 31.
52Centers for Disease Control and Prevention. Licensure of a 13 -valent pneumococcal 
conjugate vaccine (PCV13) and recommendations for use among children -Advisory  
Committee on I mmunization Practices (ACIP), 2010. MMWR Morbid Mortal Wkly Rep 
59(9) :
258-61.
53Cohen R, Biscardi S, Levy C. The multifaceted impact of pneumococcal conjugate 
vaccine implementation in children in [LOCATION_009] between 2001 to 2014. Hum Vaccin 
Immunother 2016;12(2):[ADDRESS_1010662] Dis J 2012;31(3):297-301.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 10655Flasche S, Van Hoek AJ, Sheasby  E, et al. Effect of pneumococcal conjugate 
vaccination on seroty pe-specific carriage a nd invasive disease in England: a 
cross -sectional study . PLoS Med 2011;8(4):e1001017.
56Williams SR, Mernagh PJ, L ee MHT, et al. Changing epi[INVESTIGATOR_407381] a [ADDRESS_1010663] 2011;194(3):116 -
20.
57Munoz -Almagro C, Ciruela P, Esteva C, et al. Seroty pes and clones causing invasive 
pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J 
Infect2011;63(2):151- 62.
58Norton NB, Stanek RJ, Mufson MA. Routine pneumococcal vaccination of children 
provokes new patterns of seroty pes causing invasive pneumococcal disease in adults 
and children. Am J Med Sci 2013;345(2):[ADDRESS_1010664] 2012;18(2):176 - 82.
60Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serot ypes and mortality  
following invasive pne umococcal disease: a population- based cohort stud y. PLoS Med 
2009;6(5):e1000081.
61Wroe PC, L ee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic 
resistance in young children before [ADDRESS_1010665] Dis J
2012;31(3) :249-54.
62Cohen R, Varon E, Doit C, et al. A 13- year survey of pneumococcal nasopharyngeal 
carriage in children with acute otitis media following PCV7 and PCV13 
implementation. Vaccine 2015;33(39):[ADDRESS_1010666] Dis 2016;62(9):1119-25. 
64Richter SS, Diekema DJ, Heilmann KP, et al. Changes in pneumococcal seroty pes and 
antimicrobial resi stance after introduction of the 13 -valent conjugate vaccine in the 
[LOCATION_002]. Antimicrob Agents Chemother 2014;58(11):6484
-9. 
65Demczuk WHB, Martin I, Griffith A, et al. Serot ype distribution of invasive 
Streptococcus pneumoniae in Canada after the introduction of the 13- valent 
pneumococcal conjugate vaccine, 2010 –2012. Can J Microbiol 2013;59(12):778 -88.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471014
Final Protocol Amendment 1, 18Oct2021
PFIZER CONFIDENTIAL
Page 10766Cohen R, Cohen JF, Chalumeau M, et al. Impact of pneumococcal conjugate vaccines 
for children in high -and non -high-income countries. Expert Rev Vaccines
2017;16(6):[ADDRESS_1010667]- PCV era: a s ystematic review and meta -
analysis. PloS One 2017;12(5):e0177113.
68Golden AR , Adam HJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance 
(CARA). Invasive Streptococcus pneumoniae in Canada, 2011 –2014: characterization 
of new candidate 15 -valent pneumococcal conjugate vaccine serot ypes 22F and 33F. 
Vaccine 2016;34(23):[ADDRESS_1010668] 2016;22(1):60.e9 -.e29.
70Waig ht PA, Andrews NJ, L adhani SN, et al. Effect of the 13 -valent pneumococcal 
conjugate vaccine on invasive pneumococcal disease in England and Wales 4 y ears 
after its introduction: an observational cohort study . Lancet Infect Dis
2015;15(5):[ADDRESS_1010669] G, Perniciaro S, et al. Effects of infant pneumococcal 
conjugate vaccination on seroty pe distribution in invasive pneumococcal disease 
among children and adults in German y. PLoS One 2015;10(7):e0131494.
72Beall B, Chochua S, Gertz RE Jr, et al. A population-based descriptive atlas of invasive 
pneumococcal strains recovered within the US during 2015- 2016 [online 
supplementary  material]. Front Microbiol 2018;9:2670. Available from: 
https://www.frontiersin.org/articles/10.3389/fmicb.2018 .[ZIP_CODE]/full#
supplementary -material . Accessed: [ADDRESS_1010670] Dis J 2014;33(2):183-9. 
74Frenck R Jr, Thompson A, Yeh SH, et al. Immunogenicity  and safety  of [ADDRESS_1010671] Dis J 2011;30(12):1086-91.
75US Food and Drug Administration. Guidance for industry : toxicity  grading scale for 
healthy  adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 
Rockville, MD: Center for Biologics Evaluation and Research; September 2007.

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	





	
'RFXPHQW 7LWOH !"#$% &'()'"%) *%+) ) , )-#.
"((+#$ #"
")-,	&*% #)# +(


%
#/+$) *

"# "# %)-
"%.' #0(#))'+$- ',$ 
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\
&&	[ZIP_CODE] ,
5
8&&		4940 ,
5[COMPANY_003]
[COMPANY_003]